UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended May ~~30, 2020~~29, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 1-5742

RITE AID CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	23-1614034 (I.R.S. Employer Identification No.)

30 Hunter Lane, Camp Hill, Pennsylvania (Address of principal executive offices)	17011 (Zip Code)

Registrant’s telephone number, including area code: (717) 761-2633.

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):

Not Applicable

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $1.00 par value		RAD		New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “Large Accelerated Filer,” “Accelerated Filer,” “Smaller Reporting Company” and “Emerging Growth Company” in Rule 12b-2 of the Exchange Act.

Large ~~Accelerated Filer~~ ◻

Accelerated Filer ⌧

Accelerated Filer ◻

Non-Accelerated Filer ◻

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act). Yes ☐ No ⌧

The registrant had ~~54,643,179~~55,086,812 shares of its $1.00 par value common stock outstanding as of June ~~22, 2020.~~23, 2021.

Table of Contents

RITE AID CORPORATION

TABLE OF CONTENTS


	Cautionary Statement Regarding Forward-Looking Statements	3

	PART I FINANCIAL INFORMATION

ITEM 1.	Financial Statements (unaudited):
	Condensed Consolidated Balance Sheets as of May ~~30, 2020~~29, 2021 and February ~~29, 2020~~27, 2021	5
	Condensed Consolidated Statements of Operations for the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~	6
	Condensed Consolidated Statements of Comprehensive Loss for the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~	7
	Condensed Consolidated Statements of Stockholders’ Equity for the Thirteen Week Period Ended May 29, 2021	8
	Condensed Consolidated Statements of Stockholders’ Equity for the Thirteen Week Period Ended May 30, 2020	8
	~~Condensed Consolidated Statements of Stockholders’ Equity for the Thirteen Week Period Ended June 1, 2019~~	9
	Condensed Consolidated Statements of Cash Flows for the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~	10
	Notes to Condensed Consolidated Financial Statements	11
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations	3739
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	5253
ITEM 4.	Controls and Procedures	5354

	PART II OTHER INFORMATION

ITEM 1.	Legal Proceedings	5455
ITEM 1A.	Risk Factors	5455
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	55
ITEM 3.	Defaults Upon Senior Securities	55
ITEM 4.	Mine Safety Disclosures	55
ITEM 5.	Other Information	55
ITEM 6.	Exhibits	5655

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.

Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

●

the impact of widespread health developments, including the continued impact of the global coronavirus (“COVID-19”) pandemic, and the responses thereto (such as ~~voluntary and in some cases, mandatory~~ quarantines, ~~as well as~~ shut downs and other restrictions on travel and commercial, social and other activities), including changing consumer behavior and preferences and the reinstitution of more stringent regulations (including mandatory stay at home orders and the availability, rollout and supply chain of vaccines to treat the virus), which could materially and adversely affect, among other things, the economic, ~~and~~ financial ~~markets~~ and labor ~~resources of the locations~~markets in which we operate, access to credit, our front-end and pharmaceutical operations, supply chain, associates and executive and administrative personnel. These widespread health developments, or an increase in the number of cases, could also materially and adversely affect our third-party service providers, including suppliers, vendors and business partners, and ~~customers and the demand for our products. These developments could~~customers. The COVID-19 pandemic may result in ~~recessionary economic conditions which could negatively~~further shutdowns or have a negative impact on our ~~front-end sales~~cough, cold and ~~e-commerce business.~~flu sales. Any of these developments could result in a material adverse effect on our business, financial conditions and results of operations;

●

our ability to successfully implement RxEvolution, attract and retain a sufficient number of our ~~new business strategy (including any delays or adjustments as a result of COVID-19)~~target consumers, integrate acquisitions, obtain permits required for store remodels, and improve the operating performance of our stores;

●

our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms, and our ability to satisfy our obligations and the other covenants contained in our debt agreements;

●

the nature, cost and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations, including those related to Opioids, “usual and customary” pricing or other matters;

●

general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions, civil unrest (including any resulting store closures, damage, or loss of inventory), as well as other factors specific to the markets in which we operate;

●

the severity and resulting impact of ~~private~~the cough, cold and ~~public third party payors’ continued reduction in prescription drug reimbursement rates and efforts~~flu season;

●

the impact on retail pharmacy business as pharmacy benefit management (“PBM”) payors incent or mandate movement away from retail pharmacies to ~~encourage~~PBM mail ~~order;~~order pharmacies;

●

our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs;

●

the risk that we may experience shortages in our generic drug supply due to replenishment delays resulting from COVID-19, which could result in the substitution of generic drugs with brand drugs, which generally have a lower profit margin;

●

~~the risk that~~ changes in federal or state laws or regulations, including to those relating to labor or wages, the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or ~~"ACA"~~“ACA”), and decisions of the United States Supreme Court regarding those and other matters relevant to the Company or its operations, and any regulations enacted thereunder may occur;

●

the impact of the loss of one or more major third party payor contracts and the risk that providers and state contract changes may occur;

●

the risk that we may need to take further impairment charges if our future results do not meet our expectations;

Table of Contents

●

~~our ability to refinance our indebtedness on terms favorable to us;~~

●

our ability to sell our ~~calendar 2020~~ Centers of Medicare and Medicaid Services (“CMS”) ~~receivable,~~receivables, in whole or in part, which could negatively impact our leverage ratio if we do not consummate a sale;

~~Table of Contents~~

●

our ability to grow prescription count and realize front-end sales growth;

●

~~the continued integration of our new senior management team and our ability to realize the benefits from our organizational restructuring;~~

●

our ability to achieve cost savings ~~through~~and the other benefits of our organizational ~~restructurings~~restructuring within our anticipated timeframe, if at all;

●

decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges;

●

our ability to manage expenses and our investments in working capital;

●

the continued impact of gross margin pressure in the ~~pharmacy benefit management (“PBM”)~~PBM industries due to continued consolidation and client demand for lower prices while providing enhanced service offerings;

●

risks related to ~~compromises~~breaches of our information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

●

our ability to maintain our current pharmacy services business and obtain new pharmacy services business, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations and the risk that we cannot meet client guarantees;

●

our ability to ~~maintain~~manage our ~~current~~ Medicare Part D ~~business and obtain new Medicare Part D business, as a result of the annual Medicare Part D competitive bidding process~~Plan medical loss ratio (“MLR”) and meet the financial obligations of the plan;

●

the risk that we could experience deterioration in our ~~bid;~~current Star rating with the CMS or incur CMS penalties and/or sanctions;

●

the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

●

changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies;

●

~~the risk that we could experience deterioration in our current Star rating with the CMS or incur CMS penalties and/or sanctions;~~

●

~~the nature, cost~~ and ~~outcome of pending and future litigation and other legal or regulatory proceedings, and governmental investigations;~~

●

other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the “SEC”).

We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations” included herein and in our Annual Report on Form 10-K for the fiscal year ended February ~~29, 2020, which we filed with the SEC on April~~ 27, ~~2020~~2021 (the “Fiscal ~~2020 10-K"~~2021 10-K”), as well as in “Part I – Item 1A. Risk Factors” of the Fiscal ~~2020~~2021 10-K, ~~and in “Part II – Item 1A. Risk Factors” in this Quarterly Report~~which we filed with the SEC on ~~Form 10-Q.~~April 27, 2021. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of the risk factors described herein and in our Fiscal ~~2020~~2021 10-K.

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(unaudited)


		May 30,		February 29,		May 29,		February 27,
		2020		2020		2021		2021
ASSETS
Current assets:
Cash and cash equivalents		$	288,316	$	218,180	$	118,480	$	160,902
Accounts receivable, net			1,592,799		1,286,785		1,612,596		1,462,441
Inventories, net of LIFO reserve of $527,574 and $539,640			1,890,024		1,921,604
Inventories, net of LIFO reserve of $481,866 and $485,859							1,856,968		1,864,890
Prepaid expenses and other current assets			107,672		181,794		96,908		106,941
Current assets held for sale			—		92,278
Total current assets			3,878,811		3,700,641		3,684,952		3,595,174
Property, plant and equipment, net			1,180,346		1,215,838		1,074,596		1,080,499
Operating lease right-of-use assets			2,894,333		2,903,256		3,013,577		3,064,077
Goodwill			1,108,136		1,108,136		1,108,136		1,108,136
Other intangibles, net			316,204		359,491		325,882		340,519
Deferred tax assets			16,680		16,680		14,964		14,964
Other assets			126,364		148,327		129,339		132,035
Total assets		$	9,520,874	$	9,452,369	$	9,351,446	$	9,335,404
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations		$	8,066	$	8,840	$	7,261	$	6,409
Accounts payable	��		1,460,325		1,484,081		1,537,469		1,437,421
Accrued salaries, wages and other current liabilities			679,322		746,318		677,151		642,364
Current portion of operating lease liabilities			490,202		490,161		517,602		516,752
Current liabilities held for sale			—		37,063
Total current liabilities			2,637,915		2,766,463		2,739,483		2,602,946
Long-term debt, less current maturities			3,321,972		3,077,268		3,014,517		3,063,087
Long-term operating lease liabilities			2,694,929		2,710,347		2,771,797		2,829,293
Lease financing obligations, less current maturities			18,590		19,326		16,162		16,711
Other noncurrent liabilities			233,679		204,438		205,507		208,213
Total liabilities			8,907,085		8,777,842		8,747,466		8,720,250
Commitments and contingencies			—		—		—		—
Stockholders’ equity:
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 54,675 and 54,716			54,675		54,716
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 55,093 and 55,143							55,093		55,143
Additional paid-in capital			5,892,720		5,890,903		5,898,951		5,897,168
Accumulated deficit			(5,285,735)		(5,222,194)		(5,326,160)		(5,313,103)
Accumulated other comprehensive loss			(47,871)		(48,898)		(23,904)		(24,054)
Total stockholders’ equity			613,789		674,527		603,980		615,154
Total liabilities and stockholders’ equity		$	9,520,874	$	9,452,369	$	9,351,446	$	9,335,404

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)

Thirteen Week Period Ended

May 30, 2020

June 1, 2019
Revenues

$
6,027,376

$
5,372,589
Costs and expenses:

Cost of revenues

4,829,057

4,245,866
Selling, general and administrative expenses

1,197,147

1,162,652
Lease termination and impairment charges

3,753

478
Intangible asset impairment charges

29,852

—
Interest expense

50,547

58,270
Gain on sale of assets, net

(2,260)

(2,712)

6,108,096

5,464,554
Loss from continuing operations before income taxes

(80,720)

(91,965)
Income tax (benefit) expense

(8,018)

7,374
Net loss from continuing operations

(72,702)

(99,339)
Net income (loss) from discontinued operations, net of tax

9,161

(320)
Net loss

$
(63,541)

$
(99,659)
Computation of loss attributable to common stockholders:

Loss from continuing operations attributable to common stockholders—basic and diluted

$
(72,702)

$
(99,339)
Income (loss) from discontinued operations attributable to common stockholders—basic and diluted

9,161

(320)
Loss attributable to common stockholders—basic and diluted

$
(63,541)

$
(99,659)
Basic and diluted loss per share:

Continuing operations

$
(1.36)

$
(1.88)
Discontinued operations

$
0.17

$
0.00
Net basic and diluted loss per share

$
(1.19)

$
(1.88)


	Thirteen Week Period Ended
	May 29, 2021		May 30, 2020
Revenues	$	6,160,985	$	6,027,376
Costs and expenses:
Cost of revenues		4,876,110		4,829,057
Selling, general and administrative expenses		1,245,362		1,197,147
Facility exit and impairment charges		8,831		3,753
Intangible asset impairment charges		—		29,852
Interest expense		49,121		50,547
Loss on debt retirements, net		396		—
Gain on sale of assets, net		(6,558)		(2,260)
		6,173,262		6,108,096
Loss from continuing operations before income taxes		(12,277)		(80,720)
Income tax expense (benefit)		780		(8,018)
Net loss from continuing operations		(13,057)		(72,702)
Net income from discontinued operations, net of tax		—		9,161
Net loss	$	(13,057)	$	(63,541)
Computation of loss attributable to common stockholders:
Loss from continuing operations attributable to common stockholders—basic and diluted	$	(13,057)	$	(72,702)
Income from discontinued operations attributable to common stockholders—basic and diluted		—		9,161
Loss attributable to common stockholders—basic and diluted	$	(13,057)	$	(63,541)
Basic and diluted (loss) income per share:
Continuing operations	$	(0.24)	$	(1.36)
Discontinued operations	$	0	$	0.17
Net basic and diluted loss per share	$	(0.24)	$	(1.19)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(unaudited)


	Thirteen Week Period Ended				Thirteen Week Period Ended
	May 30, 2020		June 1, 2019		May 29, 2021		May 30, 2020
Net loss	$	(63,541)	$	(99,659)	$	(13,057)	$	(63,541)
Other comprehensive income (loss):
Other comprehensive income:
Defined benefit pension plans:
Amortization of net actuarial losses included in net periodic pension cost, net of $0 and $0 tax expense		911		415
Amortization of net actuarial losses included in net periodic pension cost, net of $0 and $0 income tax expense						123		911
Change in fair value of interest rate cap		116		(656)		27		116
Total other comprehensive income (loss)		1,027		(241)
Total other comprehensive income						150		1,027
Comprehensive loss	$	(62,514)	$	(99,900)	$	(12,907)	$	(62,514)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except per share amounts)

(unaudited)


								Accumulated											Accumulated
				Additional				Other							Additional				Other
	Common Stock			Paid-In		Accumulated		Comprehensive				Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Loss		Total		Shares	Amount		Capital		Deficit		Loss		Total
BALANCE FEBRUARY 29, 2020	54,716	$	54,716	$	5,890,903	$	(5,222,194)	$	(48,898)	$	674,527
BALANCE FEBRUARY 27, 2021												55,143	$	55,143	$	5,897,168	$	(5,313,103)	$	(24,054)	$	615,154
Net loss							(63,541)				(63,541)							(13,057)				(13,057)
Other comprehensive loss:
Changes in Defined Benefit Plans, net of $0 tax expense									911		911									123		123
Change in fair value of interest rate cap									116		116									27		27
Comprehensive loss											(62,514)											(12,907)
Issuance of restricted stock	19		19		(19)						—
Exchange of restricted shares for taxes	(7)		(7)		(92)						(99)	(2)		(2)		(33)						(35)
Cancellation of restricted stock	(53)		(53)		53						—	(48)		(48)		48						—
Amortization of restricted stock balance					1,725						1,725					1,618						1,618
Stock-based compensation expense					150						150	—		—		150						150
BALANCE MAY 30, 2020	54,675	$	54,675	$	5,892,720	$	(5,285,735)	$	(47,871)	$	613,789
BALANCE MAY 29, 2021												55,093	$	55,093	$	5,898,951	$	(5,326,160)	$	(23,904)	$	603,980

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except per share amounts)

(unaudited)

Accumulated

Additional

Other

Common Stock

Paid-In

Accumulated

Comprehensive


Shares

Amount

Capital

Deficit

Loss

Total
BALANCE MARCH 2, 2019

54,016

$
54,016

$
5,876,977

$
(4,713,244)

$
(31,059)

$
1,186,690
Net loss

(99,659)

(99,659)
Other comprehensive loss:

Changes in Defined Benefit Plans, net of $0 tax expense

415

415
Change in fair value of interest rate cap

(656)

(656)
Comprehensive loss

(99,900)
Adoption of ASU 2016-02

(56,776)

(56,776)
Exchange of restricted shares for taxes

(5)

(5)

(190)

(195)
Cancellation of restricted stock

(178)

(178)

178

—
Amortization of restricted stock balance

5,016

5,016
Stock-based compensation expense

382

382
BALANCE JUNE 1, 2019

53,833

$
53,833

$
5,882,363

$
(4,869,679)

$
(31,300)

$
1,035,217


								Accumulated
				Additional				Other
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Loss		Total
BALANCE FEBRUARY 29, 2020	54,716	$	54,716	$	5,890,903	$	(5,222,194)	$	(48,898)	$	674,527
Net loss							(63,541)				(63,541)
Other comprehensive loss:
Changes in Defined Benefit Plans, net of $0 tax expense									911		911
Change in fair value of interest rate cap									116		116
Comprehensive loss											(62,514)
Issuance of restricted stock	19		19		(19)						—
Exchange of restricted shares for taxes	(7)		(7)		(92)						(99)
Cancellation of restricted stock	(53)		(53)		53						—
Amortization of restricted stock balance					1,725						1,725
Stock-based compensation expense					150						150
BALANCE MAY 30, 2020	54,675	$	54,675	$	5,892,720	$	(5,285,735)	$	(47,871)	$	613,789

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

Thirteen Week Period Ended

May 30, 2020

June 1, 2019
Operating activities:

Net loss

$
(63,541)

$
(99,659)
Net income (loss) from discontinued operations, net of tax

9,161

(320)
Net loss from continuing operations

$
(72,702)

$
(99,339)
Adjustments to reconcile to net cash used in operating activities of continuing operations:

Depreciation and amortization

79,103

83,926
Lease termination and impairment charges

3,753

478
Intangible asset impairment charges

29,852

—
LIFO (credit) charge

(12,066)

7,489
Gain on sale of assets, net

(2,260)

(2,712)
Stock-based compensation expense

1,874

5,380
Changes in operating assets and liabilities:

Accounts receivable

(308,636)

(17,565)
Inventories

43,647

(11,454)
Accounts payable

13,320

(75,893)
Operating lease right-of-use assets and operating lease liabilities

(6,595)

(11,893)
Other assets

99,177

22,513
Other liabilities

13,263

47,831
Net cash used in operating activities of continuing operations

(118,270)

(51,239)
Investing activities:

Payments for property, plant and equipment

(28,459)

(40,981)
Intangible assets acquired

(10,715)

(8,210)
Proceeds from dispositions of assets and investments

2,755

658
Net cash used in investing activities of continuing operations

(36,419)

(48,533)
Financing activities:

Net proceeds from revolver

242,000

125,000
Principal payments on long-term debt

(1,298)

(1,780)
Change in zero balance cash accounts

(26,567)

36,387
Payments for taxes related to net share settlement of equity awards

(99)

(195)
Deferred financing costs paid

(1,332)

(186)
Net cash provided by financing activities of continuing operations

212,704

159,226
Cash flows from discontinued operations:

Operating activities of discontinued operations

(82,189)

(13,877)
Investing activities of discontinued operations

94,310

523
Financing activities of discontinued operations

—

—
Net cash provided by (used in) discontinued operations

12,121

(13,354)
Increase in cash and cash equivalents

70,136

46,100
Cash and cash equivalents, beginning of period

218,180

144,353
Cash and cash equivalents, end of period

$
288,316

$
190,453


	Thirteen Week Period Ended
	May 29, 2021		May 30, 2020
Operating activities:
Net loss	$	(13,057)	$	(63,541)
Net income from discontinued operations, net of tax		—		9,161
Net loss from continuing operations	$	(13,057)	$	(72,702)
Adjustments to reconcile to net cash provided by (used in) operating activities of continuing operations:
Depreciation and amortization		75,859		79,103
Facility exit and impairment charges		8,831		3,753
Intangible asset impairment charges		—		29,852
LIFO credit		(3,993)		(12,066)
Gain on sale of assets, net		(6,558)		(2,260)
Stock-based compensation expense		2,811		1,874
Loss on debt retirements, net		396		—
Changes in operating assets and liabilities:
Accounts receivable		(149,487)		(308,636)
Inventories		11,918		43,647
Accounts payable		50,527		13,320
Operating lease right-of-use assets and operating lease liabilities		(5,909)		(6,595)
Other assets		7,978		99,177
Other liabilities		34,559		13,263
Net cash provided by (used in) operating activities of continuing operations		13,875		(118,270)
Investing activities:
Payments for property, plant and equipment		(59,164)		(28,459)
Intangible assets acquired		(5,436)		(10,715)
Proceeds from dispositions of assets and investments		2,448		2,755
Proceeds from sale-leaseback transactions		7,456		—
Net cash used in investing activities of continuing operations		(54,696)		(36,419)
Financing activities:
Net proceeds from revolver		39,000		242,000
Principal payments on long-term debt		(91,941)		(1,298)
Change in zero balance cash accounts		51,957		(26,567)
Financing fees paid for early debt redemption		(2)		—
Payments for taxes related to net share settlement of equity awards		(35)		(99)
Deferred financing costs paid		(580)		(1,332)
Net cash (used in) provided by financing activities of continuing operations		(1,601)		212,704
Cash flows from discontinued operations:
Operating activities of discontinued operations		0		(82,189)
Investing activities of discontinued operations		0		94,310
Financing activities of discontinued operations		0		0
Net cash provided by discontinued operations		0		12,121
(Decrease) increase in cash and cash equivalents		(42,422)		70,136
Cash and cash equivalents, beginning of period		160,902		218,180
Cash and cash equivalents, end of period	$	118,480	$	288,316

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

1. Basis of Presentation and Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen week period ended May ~~30, 2020~~29, 2021 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal ~~2020~~2021 10-K.

Revenue Recognition

The following table disaggregates the Company’s revenue by major source in each segment for the thirteen week periods ended May 29, 2021 and May 30, ~~2020 and June 1, 2019:~~2020:


	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
In thousands	(13 weeks)		(13 weeks)		(13 weeks)		(13 weeks)
Retail Pharmacy segment:
Pharmacy sales	$	2,625,544	$	2,563,244	$	2,997,044	$	2,625,544
Front-end sales		1,465,467		1,265,361		1,321,699		1,465,467
Other revenue		32,260		36,203		32,939		32,260
Total Retail Pharmacy segment		4,123,271		3,864,808		4,351,682		4,123,271
Pharmacy Services segment		1,977,246		1,566,292		1,872,282		1,977,246
Intersegment elimination		(73,141)		(58,511)		(62,979)		(73,141)
Total revenue	$	6,027,376	$	5,372,589	$	6,160,985	$	6,027,376

The Retail Pharmacy segment ~~offers~~offered a chain-wide loyalty card program titled wellness+. Individual customers ~~are~~were able to become members of the wellness+ program. Members participating in the wellness+ loyalty card program ~~earn~~earned points on a calendar year basis for eligible front-end merchandise purchases and qualifying prescription purchases. The existing wellness+ program was terminated as of July 1, 2020, with benefits earned as of that date available to be used through the end of calendar 2020. In December 2020, the Company granted a temporary extension of benefits to previous members that were eligible for a discount as of December 31, 2020 such that those prior members will be eligible to continue to receive that discount on purchases made through December 31, 2021 with no additional purchase requirement. New and existing customers who were not already eligible for “Gold” benefits have the opportunity to earn additional discounts on purchases made through December 31, 2021.

~~Effective~~Prior to its termination, effective January 1, 2020, members ~~reach~~reached specific wellness+ tiers based on points accumulated during the six calendar month periods between January 1^st and June 30^th, and July 1^st through December 31^st, which ~~entitles~~entitled such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 500 points during the six calendar month period between January 1^st and June 30^th achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front-end merchandise for the

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

remaining portion of that six calendar month period and for the following six calendar months. There is also a similar “Silver” level with a lower threshold and benefit level. Prior to January 1, 2020, the wellness+ tiers were based on points accumulated for a full calendar year, and entitled such customers to wellness+ benefits for the remainder of that calendar year and also the next calendar year.

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

Points earned pursuant to the wellness+ program represent a performance obligation and the Company allocates revenue between the merchandise purchased and the wellness+ points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness+ points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As members receive discounted front-end merchandise or when the benefit period expires, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. For the thirteen week period ended May ~~30, 2020,~~29, 2021, the Company recognized ~~approximately $11,600~~$1,613 of deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of ~~$41,089~~$2,141 as of May ~~30, 2020,~~29, 2021, which is included in other current liabilities. The Retail Pharmacy segment had accrued contract liabilities of ~~$52,668~~$3,754 as of February ~~29, 2020,~~27, 2021, which is included in other current liabilities.

Recently Adopted Accounting Pronouncements

In March 2020, the Securities and Exchange Commission (SEC) adopted final rules that amend the financial disclosure requirement for guarantors of registered debt securities in Rule 3-10 of Regulation S-X. The new rules amend and streamline the disclosures required by guarantors and issuers of guaranteed securities. Among other things, the new disclosures may be located outside the financial statements. The new rule is effective January 4, 2021, and early adoption is permitted. The Company elected to early adopt the new rule on May 30, 2020. Accordingly, the revised condensed consolidating financial information is presented in Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations.

~~In August 2018,~~December 2019, the FASB issued ASU ~~No. 2018-15,~~2019-12, ~~Intangibles-Goodwill~~Simplifying the Accounting for Income Taxes (Topic 740). This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the recognition of deferred tax liabilities and ~~Other-Internal-Use Software (Subtopic 350-40), which is intended to provide entities with additional guidance to determine which software implementation costs to capitalize~~the methodology for calculating income taxes in the interim period. The amendments also improve consistent application of and ~~which costs to expense. The~~simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU ~~will allow entities to capitalize costs for implementation activities during the application development stage. ASU No. 2018-15~~ is effective for fiscal years ~~and interim periods within those years~~ beginning after December 15, ~~2019~~2020 (fiscal ~~2021)~~2022). ~~Early adoption of~~The Company adopted ASU ~~2018-15 is permitted. The~~2019-12 effective February 28, 2021 and the adoption of this ~~ASU~~standard did not have a material impact on the Company’s financial ~~position, results of operations and cash flows.~~

~~In June 2016, the FASB issued ASU 2016-13,~~ ~~Measurement of Credit Losses on Financial Instruments~~, which adds to U.S. GAAP an impairment model (known as the current expected credit loss ("CECL") model), that is based on expected losses rather than incurred losses. Under ASU 2016-13, an entity will recognize, as an allowance, its estimate of lifetime expected credit losses, which the FASB believes will result in more timely recognition of such losses. ASU 2016-13 impacts non-banks as most non-banks have financial instruments or other assets (e.g. trade, contract and lease receivables, financial guarantees, loans and loan commitments and held-to-maturity debt securities). The adoption of this ASU did not have a material impact on the Company’s financial position, results of operations and cash flows.position.

~~Recently Issued Accounting Pronouncements Not Yet Adopted~~

2. Acquisition

On December 18, 2020, pursuant to that certain stock purchase agreement, dated as of October 7, 2020, by and between the Company and Bartell Drug Company (“Bartell”), the Company acquired Bartell (the “Acquisition”), a Washington corporation, for approximately $89,724 in cash, subject to certain customary post-closing working capital adjustments. Bartell operates 67 retail drug stores and 1 distribution center in the greater Seattle, Washington area. Bartell will operate as a 100 percent owned subsidiary of the Company within its Retail Pharmacy segment.

The Company financed the Acquisition with borrowings under its Senior Secured Revolving Credit Facility together with cash on hand. The closing balance sheet has not yet been finalized, and therefore, the final purchase price and related purchase price allocation of the Acquisition is subject to change.

~~In August 2018, the FASB issued ASU 2018-14,~~ ~~Compensation - Retirement benefits (Topic 715-20)~~~~. This ASU amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans.~~ The ASU eliminates the requirement to disclose the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year. The ASU also removes the disclosure requirementsCompany’s condensed consolidated financial statements for the ~~effects~~thirteen weeks ended May 29, 2021 include Bartell’s results of ~~a one-percentage-point change~~operations. The Company’s financial statements reflect preliminary purchase accounting adjustments in accordance with ASC 805 “Business Combinations”, whereby the purchase price was preliminarily allocated to the assets acquired and liabilities assumed based upon their estimated fair values on the ~~assumed health care costs and the effect of this change in rates on service cost, interest cost and the benefit obligation for postretirement health care benefits. This~~Acquisition date.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

~~ASU~~The following allocation of the purchase price and the estimated transaction costs is ~~effective~~preliminary and is based on information available to the Company’s management at the time the consolidated financial statements were prepared. Accordingly, the allocation is subject to change and the impact of such changes may be material.


Preliminary purchase price
Cash consideration	$	89,724
Total		89,724
Preliminary purchase price allocation
Cash and cash equivalents	$	3,494
Accounts receivable		24,188
Inventories		69,046
Prepaid expenses and other current assets		1,857
Total current assets		98,585
Property and equipment		28,229
Operating lease right-of-use assets		143,651
Intangible assets(1)		68,700
Other assets		1,805
Total assets acquired		340,970
Accounts payable		24,166
Accrued salaries, wages and other current liabilities		18,386
Current portion of operating lease liabilities		24,617
Total current liabilities		67,169
Long-term operating lease liabilities		124,023
Total liabilities assumed		191,192
Deferred tax liabilities recorded on purchase		12,349
Net assets acquired		137,429
Bargain purchase gain		(47,705)
Total purchase price	$	89,724

(1) Intangible assets are recorded at estimated fair value, as determined by management based on available information which includes a preliminary valuation prepared by an independent third party. The fair values assigned to identifiable intangible assets were determined through the use of the income approach, specifically the relief from royalty and the multi-period excess earnings methods. The major assumptions used in arriving at the estimated identifiable intangible asset values included management’s preliminary estimates of future cash flows, discounted at an appropriate rate of return which are based on the weighted average cost of capital for ~~fiscal years ending after December 15,~~both the Company and other market participants, projected customer attrition rates, as well as applicable royalty rates for comparable assets. The useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows. The estimated fair value of intangible assets and related useful lives as included in the preliminary purchase price allocation include:

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and ~~must be applied on~~share information in thousands, except per share amounts)

(unaudited)


	Estimated Fair Value		Estimated Useful Life (In Years)
Prescription files	$	54,300	10
Tradename		14,400	Indefinite
Total	$	68,700

The Acquisition resulted in a ~~retrospective basis.~~bargain purchase gain of $47,705 primarily due to fair value adjustments related to prescription files and the tradename compared to book values. The Company believes that the bargain purchase gain was primarily the result of the decision by the Bartell stockholders to sell their interests as Bartell had been experiencing increasing borrowings under its credit agreements to meet its operating needs and increasing net losses. The agreed upon purchase price reflected the fact the seller would have needed to incur further significant debt to cover the operating costs of Bartell, which would have required amendments to its credit arrangements. With the Company’s existing infrastructure, scale and expertise, the Company believes that it has access to the necessary synergies to allow necessary operational improvements to be implemented more efficiently than the seller was capable of.

During the thirteen week periods ended May 29, 2021 and May 30, 2020, acquisition costs of $3,886 and $0 were expensed as incurred. The following unaudited pro forma combined financial data gives effect to the Acquisition as if it had occurred as of March 1, 2019.

The unaudited combined pro forma results do not include any incremental cost savings that may result from the integration. The adjustments are based on information available to the Company at this time. Accordingly, the adjustments are subject to change and the impact of such changes may be material.

The unaudited combined pro forma information is ~~evaluating~~for informational purposes only. The pro forma information is not necessarily indicative of what the ~~effect~~combined company’s results actually would have been had the Acquisition been completed as of ~~adopting this new accounting guidance, but~~the beginning of the periods as indicated. In addition, the unaudited pro forma information does not ~~expect adoption will have a material impact on~~purport to project the ~~Company’s financial position.~~future results of the combined company.


	May 29,		May 30,
	2021		2020
	(13 weeks)		(13 weeks)
	Pro forma		Pro forma
Net revenues as reported	$	6,160,985	$	6,027,376
Supplemental Pro forma revenues	$	6,160,985	$	6,164,616

Net loss as reported	$	(13,057)	$	(63,541)
Supplemental Pro forma net loss	$	(13,057)	$	(70,356)

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

2.3. Restructuring

Beginning in fiscal 2019, the Company initiated a series of restructuring plans designed to reorganize its executive management team, reduce managerial layers, and consolidate roles. In March 2020, the Company announced the details of its RxEvolution strategy, which includes building tools to work with regional health plans to improve patient health outcomes, rationalizing SKU’s in its front-end offering to free up working capital and update its merchandise assortment, assessing its pricing and promotional strategy, rebranding its retail pharmacy and ~~EnvisionRxOptions, soon to be rebranded Elixir,~~pharmacy services business, launching its Store of the Future format and further reducing SG&A and headcount, including integrating certain back office functions in the Pharmacy Services segment both within the segment and across Rite Aid. Other strategic initiatives include the expansion of the Company’s digital business, movement to a common client platform at Elixir and investments in talent in sales and underwriting at Elixir.

For the thirteen week period ended May 29, 2021, the Company incurred total restructuring-related costs of $5,932, which are included as a component of SG&A. These costs are as follows:


	Retail Pharmacy		Pharmacy
	segment		Services segment		Total

Restructuring-related costs
Severance and related costs associated with ongoing reorganization efforts (a)	$	—	$	506	$	506
Non-executive retention costs associated with the March 2019 reorganization (b)		—		—		—
Professional and other fees relating to restructuring activities (c)		1,621		3,805		5,426
Total restructuring-related costs	$	1,621	$	4,311	$	5,932

For the thirteen week period ended May 30, 2020, the Company incurred total restructuring-related costs of $35,735, of which $9,972 is included as a component of SG&A and $25,763 is included as a component of cost of revenues. These costs are as follows:


	Retail Pharmacy		Pharmacy
	segment		Services segment		Total

Restructuring-related costs
Severance and related costs associated with ongoing reorganization efforts (a)	$	4,559	$	252	$	4,811
Non-executive retention costs associated with the March 2019 reorganization (b)		855		(226)		629
Professional and other fees relating to restructuring activities (c)		4,532		—		4,532
SKU optimization charges (d)		25,763		—		25,763
Total restructuring-related costs	$	35,709	$	26	$	35,735

In addition, during the thirteen week period ended May 30, 2020, the Company incurred intangible asset impairment charges of $29,852 in connection with its rebranding initiatives as described in Note ~~10,~~11, Goodwill and Other Intangible Assets.

1315

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

~~For the thirteen week period ended June 1, 2019, the Company incurred total restructuring-related costs of $43,350, which are included as a component of SG&A. These costs are as follows:~~

Retail Pharmacy

Pharmacy


segment

Services segment

Total

Restructuring-related costs

Severance and related costs associated with ongoing reorganization efforts (a)

$
25,272

$
1,804

$
27,076
Non-executive retention costs associated with the March 2019 reorganization (b)

4,499

2,165

6,664
Professional and other fees relating to restructuring activities (c)

9,610

—

9,610
Total restructuring-related costs

$
39,381

$
3,969

$
43,350

A summary of activity for the thirteen week period ended May ~~30, 2020~~29, 2021 in the restructuring-related liabilities associated with the programs noted above, which is included in accrued salaries, wages and other current liabilities, is as follows:


	Severance and related				Professional and					Severance and related				Professional and
	costs (a)		Retention costs (b)		other fees (c)		Total			costs (a)		Retention costs (b)		other fees (c)		Total

Balance at February 29, 2020	$	36,228	$	6,432	$	2,394	$	45,054
Balance at February 27, 2021									Balance at February 27, 2021	$	12,657	$	—	$	2,833	$	15,490
Additions charged to expense		4,811		629		4,532		9,972			506		—		5,426		5,932
Cash payments		(13,055)		—		(5,046)		(18,101)			(4,826)		—		(7,636)		(12,462)
Balance at May 30, 2020	$	27,984	$	7,061	$	1,880	$	36,925
Balance at May 29, 2021										$	8,337	$	—	$	623	$	8,960

(a)	– Severance and related costs reflect severance accruals, executive search fees, outplacement services and other similar charges associated with ongoing reorganization efforts.

(b)	– As part of its March 2019 reorganization, the Company incurred costs with the implementation of a retention plan for certain of its key associates.

(c)	– Professional and other fees include costs incurred in connection with the identification and implementation of initiatives associated with restructuring activities.

(d)	– Inventory reserve on product lines the Company is exiting and will no longer carry as part of its rebranding initiative.

The Company anticipates incurring approximately ~~$60,000~~$30,000 during fiscal ~~2021~~2022 in connection with its continued restructuring activities.

3.4. Asset Sale to WBA

On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with Walgreens Boots Alliance, Inc. (“WBA”) and Walgreen Co., an Illinois corporation and 100% owned subsidiary of WBA (“Buyer”), which amended and restated in its entirety the previously disclosed Asset Purchase Agreement, dated as of June 28, 2017, by and among the Company, WBA and Buyer (the “Original Asset Purchase Agreement”). Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement,

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

Buyer purchased from the Company 1,932 stores (the “Acquired Stores”), 3 distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of $4,375,000, on a cash-free, debt-free basis (the “Asset Sale” or “Sale”). The Company completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA, and received cash proceeds of $4,156,686.

During fiscal 2019, the Company completed the sale of 1 of its distribution centers and related assets to WBA for proceeds of $61,251. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $14,151, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended March 2, 2019. During fiscal 2020, the Company completed the sale of the second distribution center and related assets to WBA for proceeds of $62,774. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $19,268, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended February 29, 2020. During the first quarter of fiscal 2021, the Company completed the sale of the final distribution center and related assets to WBA for proceeds of ~~$94,289.~~

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

$94,289. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $12,690, which ~~has been~~was included in the results of operations and cash flows of discontinued operations during the thirteen week period ended May 30, 2020. The transfer of the final distribution center and related assets constitutes the final closing under the Amended and Restated Asset Purchase Agreement.

The Company had agreed to provide transition services to Buyer for up to three years after the initial closing of the Sale. Under the terms of the Transition Services Agreement (“TSA”), the Company provided various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. The term of the TSA had been extended to October 17, 2020, unless earlier terminated. In connection with these services, the Company purchased the related inventory and incurred cash payments for the selling, general and administrative activities, which, the Company billed on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen week periods ended May 29, 2021 and May 30, 2020 were $0 and ~~June 1, 2019 were~~ $31,005, ~~and $1,192,791,~~ respectively, of which ~~$4,398~~$0 and ~~$224,385~~$4,398 is included in Accounts receivable, net. The Company recorded WBA TSA fees of ~~$1,080~~$0 and ~~$14,225~~$1,080 during the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively, which are reflected as a reduction to selling, general and administrative expenses. In conjunction with the transfer of the final distribution center during the quarter ended May 30, 2020, the Company has substantially completed its obligations under the TSA. On July 14, 2020, the Company entered into a letter agreement with WBA to terminate the services under the TSA, other than certain specified services relating to real estate, accounting, tax, and accounts receivable systems that continued until October 17, 2020 and certain specified services relating to human resources to be performed after October 17, 2020.

Based on its magnitude and because the Company exited certain markets, the Sale represented a significant strategic shift that has a material effect on the Company's operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05-Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended May ~~30, 2020~~29, 2021 and February ~~29, 2020,~~27, 2021, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20.

As of February 27, 2021, there are no assets and liabilities classified as held for sale relating to the Asset Sale to WBA.

1517

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows:

May 30,

February 29,


2020

2020
Inventories

$
—

$
13,719
Property and equipment

—

43,576
Operating lease right-of-use asset

—

34,983
Current assets held for sale

$
—

$
92,278
Current portion of operating lease liabilities

$
—

$
2,002
Long-term operating lease liabilities

—

35,061
Current liabilities held for sale

$
—

$
37,063

The operating results of the discontinued operations that are reflected on the consolidated statements of operations within net income ~~(loss)~~ from discontinued operations are as follows:


	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
	(13 weeks)		(13 weeks)		(13 weeks)		(13 weeks)
Revenues	$	174	$	(88)	$	—	$	174
Costs and expenses:
Cost of revenues(a)		8		265		—		8
Selling, general and administrative expenses(a)		871		486		—		871
Gain on sale of assets, net		(14,149)		(522)		—		(14,149)
		(13,270)		229		—		(13,270)
Income (loss) from discontinued operations before income taxes		13,444		(317)
Income from discontinued operations before income taxes						—		13,444
Income tax expense		4,283		3		—		4,283
Net income (loss) from discontinued operations, net of tax	$	9,161	$	(320)
Net income from discontinued operations, net of tax					$	—	$	9,161

(a)	Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations.

The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income ~~(loss)~~ from discontinued operations only include expenses that are directly attributable to the Disposal Group.

4.5. Income (Loss) Per Share

Basic income (loss) per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company, subject to anti-dilution limitations.

1618

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Thirteen Week Period Ended				Thirteen Week Period Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
Basic and diluted income (loss) per share:
Basic and diluted loss per share:
Numerator:
Net loss from continuing operations	$	(72,702)	$	(99,339)	$	(13,057)	$	(72,702)
Net income (loss) from discontinued operations		9,161		(320)
Net income from discontinued operations						—		9,161
Loss attributable to common stockholders— basic and diluted	$	(63,541)	$	(99,659)	$	(13,057)	$	(63,541)
Denominator:
Basic weighted average shares		53,462		52,976		53,852		53,462
Outstanding options and restricted shares, net		—		—		—		—
Diluted weighted average shares		53,462		52,976		53,852		53,462
Basic and diluted income (loss) per share:
Basic and diluted (loss) income per share:
Continuing operations	$	(1.36)	$	(1.88)	$	(0.24)	$	(1.36)
Discontinued operations		0.17		0.00		-		0.17
Net basic and diluted loss per share	$	(1.19)	$	(1.88)	$	(0.24)	$	(1.19)

Due to their antidilutive effect, ~~1,264~~773 and ~~992~~1,264 potential common shares related to stock options have been excluded from the computation of diluted income (loss) per share for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. Also, excluded from the computation of diluted income (loss) per share for the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~ are restricted shares of ~~1,198~~1,240 and ~~813,~~1,198, respectively, which are included in shares outstanding.

~~5. Lease Termination~~6. Facility Exit and Impairment Charges

~~Lease termination~~Facility exit and impairment charges consist of amounts as follows:


	Thirteen Week Period				Thirteen Week Period
	Ended				Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
Impairment charges	$	2,203	$	123	$	4,313	$	2,203
Lease termination charges		—		—
Facility exit charges		1,550		355		4,518		1,550
	$	3,753	$	478	$	8,831	$	3,753

Impairment Charges

These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management’s intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.

1719

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

●

Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

●

Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

●

Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

Non-Financial Assets Measured on a Non-Recurring Basis

Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the thirteen week period ended May 29, 2021, long-lived assets from continuing operations with a carrying value of $4,313, primarily right-of-use assets in connection with leased office spaces, were written down to their fair value of $0, resulting in an impairment charge of $4,313. During the thirteen week period ended May 30, 2020, long-lived assets from continuing operations with a carrying value of $2,203, were written down to their fair value of $0, resulting in an impairment charge of $2,203. Of the $2,203, $1,919 relates to a terminated software project and $284 relates to store assets. During the thirteen week period ended June 1, 2019, long-lived assets from continuing operations with a carrying value of $123, primarily store assets, were written down to their fair value of $0, resulting in an impairment charge of $123. If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.

The following table presents fair values for those assets measured at fair value on a non-recurring basis at May 29, 2021 and May 30, ~~2020 and June 1, 2019:~~2020:


							Fair Values		Total
							as of		Charges
	Level 1		Level 2		Level 3		Impairment Date		May 29, 2021
Long-lived assets held for use	$	—	$	—	$	—	$	—	$	(4,313)
Long-lived assets held for sale	$	—	$	—	$	—	$	—	$	—
Total	$	—	$	—	$	—	$	—	$	(4,313)

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)


							Fair Values		Total
							as of		Charges
	Level 1		Level 2		Level 3		Impairment Date		May 30, 2020
Long-lived assets held for use	$	—	$	—	$	—	$	—	$	(2,203)
Long-lived assets held for sale	$	—	$	—	$	—	$	—	$	—
Total	$	—	$	—	$	—	$	—	$	(2,203)

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

~~��~~

~~Fair Values~~

~~Total~~

~~as of~~

~~Charges~~

~~Level 1~~

~~Level 2~~

~~Level 3~~

~~Impairment Date~~

~~June 1, 2019~~

~~Long-lived assets held for use~~

—

~~(123)~~

~~Long-lived assets held for sale~~

—

~~Total~~

—

~~(123)~~

The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and due to their immateriality have not been reclassified to assets held for sale.

~~Lease Termination and~~ Facility Exit Charges

As part of the Company's ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in ~~lease termination~~facility exit charges ~~lease exit costs~~ and inventory liquidation charges, as well as impairment of assets at these locations. When a store or distribution center is closed, the Company records an expense for unrecoverable costs and accrues a liability equal to the present value at current credit adjusted risk-free interest rates of any anticipated executory costs which are not included within the store or distribution center's respective lease liability under Topic 842. Other store or distribution center closing and liquidation costs are expensed when incurred.

The following table reflects changes in the Company’s closed store liability relating to closed store and distribution center charges ~~that relate to~~for new closures, changes in assumptions and interest accretion:


	Thirteen Week Period				Thirteen Week Period
	Ended				Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
Balance—beginning of period	$	2,253	$	124,046	$	3,443	$	2,253
Existing Topic 420 liabilities eliminated by recording a reduction to the ROU asset		—		(112,288)
Cash payments, net of sublease income		(83)		(2,425)
Provision for present value of executory costs for leases exited						1,708		—
Changes in assumptions and other adjustments						1,493		—
Interest accretion						7		—
Cash payments						(516)		(83)
Balance—end of period	$	2,170	$	9,333	$	6,135	$	2,170

6.7. Fair Value Measurements

The Company utilizes the three-level valuation hierarchy as described in Note 5,6, ~~Lease Termination~~Facility Exit and Impairment Charges, for the recognition and disclosure of fair value measurements.

Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature. In addition, as of May ~~30, 2020~~29, 2021 and February ~~29, 2020,~~27, 2021, the Company has ~~$7,014~~$7,043 and ~~$7,022,~~$7,041, respectively, of investments carried at amortized cost as these investments are being held to maturity, which are included as a component of other assets. The Company believes the carrying value of these investments approximates their fair value.

1921

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The fair value for LIBOR-based borrowings under the Company’s senior secured credit facility is estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long-term indebtedness was ~~$3,321,972~~$3,014,517 and ~~$3,206,395,~~$3,100,602, respectively, as of May ~~30, 2020.~~29, 2021. The carrying amount and estimated fair value of the Company's total long-term indebtedness was ~~$3,077,268~~$3,063,087 and ~~$3,021,385,~~$3,176,322, respectively, as of February ~~29, 2020.~~27, 2021.

7.8. Income Taxes

The Company recorded an income tax expense from continuing operations of $780 and an income tax benefit from continuing operations of $8,018 ~~and an income tax expense from continuing operations of $7,374~~ for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. The effective tax rate for the thirteen week periods ended May 29, 2021 and May 30, 2020 was (6.4)% and ~~June 1, 2019 was~~ 9.9% ~~and (8.0)%~~, respectively. The effective tax rate for the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~ was net of an adjustment of ~~(10.6)~~(18.5)%, and ~~(34.5)~~(10.6)%, respectively, to adjust the valuation allowance against deferred tax assets.

The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

The Company believes that it is reasonably possible that a decrease of up to ~~$13,210~~$11,851 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain. Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of ~~$1,681,399~~$1,660,547 and ~~$1,673,119,~~$1,657,562, which relates to federal and state deferred tax assets that may not be realized based on the Company's future projections of taxable income at May ~~30, 2020~~29, 2021 and February ~~29, 2020,~~27, 2021, respectively.

8.9. Medicare Part D

The Company offers Medicare Part D benefits through ~~EIC,~~Elixir Insurance (“EI”), which has contracted with CMS to be a ~~PDP~~Prescription Drug Plan (“PDP”) and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.

~~EIC~~EI is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, ~~EIC~~EI must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not ~~believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to~~

2022

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

believe these limitations on dividends and distributions materially impact its financial position. EI is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is ~~$9,675~~$14,767 as of March 31, ~~2020. EIC~~2021. EI was in excess of the minimum required amounts in these states as of May ~~30, 2020.~~29, 2021.

The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.

On February 19, 2020, the Company entered into a receivable purchase agreement (the ~~“Receivable~~“2019 Receivable Purchase Agreement”) with Bank of America, N.A. (the “Purchaser”).

Pursuant to the terms and conditions set forth in the 2019 Receivable Purchase Agreement, the Company sold $501,422 of its calendar 2019 CMS receivable for $484,547, of which $449,949 was received on February 19, ~~2020. The remaining $34,598, which is included~~2020 and the remainder was received in ~~accounts receivable, net as of May 30, 2020, is payable to the Company, subject to final CMS claim reconciliation adjustments,~~fiscal 2021 upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $16,875, which iswas included as a component of loss on sale of assets, net in the fourth quarter of fiscal 2020.

On February 19, 2020, concurrent with the 2019 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the ~~“Indemnity~~“2019 Indemnity Agreement”), whereby the Company has agreed to indemnify, reimburse and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the 2019 Indemnity Agreement. Based on its evaluation of the 2019 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the 2019 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the 2019 Indemnity Agreement.

AsOn November 12, 2020, the Company entered into a receivable purchase agreement (the “November 2020 Receivable Purchase Agreement”) with Purchaser, which was on terms similar to the 2019 Receivable Purchase Agreement.

Pursuant to the terms and conditions set forth in the November 2020 Receivable Purchase Agreement, the Company sold $464,019, a portion of ~~May 30,~~its calendar 2020 ~~accounts~~CMS receivable, ~~net included $268,312 due from CMS. As~~for $444,812, of ~~February 29, 2020, accrued salaries, wages and other current liabilities included $14,083 of amounts due to CMS.~~

~~9. Manufacturer Rebates Receivables~~

which $412,795 was received on November 12, 2020. The ~~Pharmacy Services Segment has manufacturer rebates receivables of $593,774 and $530,451~~remaining $32,017, which is included in ~~Accounts~~accounts receivable, net as of May ~~30,~~29, 2021, is payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $19,207, which is included as a component of gain on sale of assets, net.

On November 12, 2020, concurrent with the November 2020 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the “November 2020 Indemnity Agreement”), whereby the Company has agreed to indemnify, reimburse and ~~February 29, 2020, respectively.~~

~~10. Goodwill~~hold Purchaser harmless from certain liabilities and ~~Other Intangible Assets~~

There was 0 goodwill impairment charge for the thirteen week period ended May 30, 2020. At May 30, 2020 and February 29, 2020, accumulated impairment losses for the Pharmacy Services segment was $574,712.

expenses actually suffered or incurred by

2123

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

the Purchaser resulting from the occurrence of certain events as specified in the November 2020 Indemnity Agreement. Based on its evaluation of the November 2020 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the November 2020 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the November 2020 Indemnity Agreement.

On February 18, 2021, the Company entered into a receivable purchase agreement (the “February 2021 Receivable Purchase Agreement”) with Purchaser, which was on terms similar to the 2019 Receivable Purchase Agreement.

Pursuant to the terms and conditions set forth in the February 2021 Receivable Purchase Agreement, the Company sold $300,015, the remaining portion of its calendar 2020 CMS receivable, for $290,613, of which $269,912 was received on February 18, 2021. The remaining $20,701, which is included in accounts receivable, net as of May 29, 2021, is payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $9,403, which is included as a component of gain on sale of assets, net.

On February 18, 2021, concurrent with the February 2021 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the “February 2021 Indemnity Agreement”), whereby the Company has agreed to indemnify, reimburse and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the February 2021 Indemnity Agreement. Based on its evaluation of the February 2021 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the February 2021 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the February 2021 Indemnity Agreement.

As of May 29, 2021, and February 27, 2021, accounts receivable, net included $257,860 and $69,800 due from CMS.

10. Manufacturer Rebates Receivables

The Pharmacy Services Segment has manufacturer rebates receivables of $570,030 and $632,267 included in Accounts receivable, net, as of May 29, 2021 and February 27, 2021, respectively.

11. Goodwill and Other Intangible Assets

There was 0 goodwill impairment charge for the thirteen week period ended May 29, 2021. At May 29, 2021 and February 27, 2021, accumulated impairment losses for the Pharmacy Services segment was $574,712.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of May ~~30, 2020~~29, 2021 and February ~~29, 2020.~~27, 2021.


	May 30,2020								February 29, 2020								May 29, 2021								February 27, 2021
							Remaining								Remaining								Remaining								Remaining
							Weighted								Weighted								Weighted								Weighted
	Gross						Average		Gross						Average		Gross						Average		Gross						Average
	Carrying		Accumulated				Amortization		Carrying		Accumulated				Amortization		Carrying		Accumulated				Amortization		Carrying		Accumulated				Amortization
	Amount		Amortization		Net		Period		Amount		Amortization		Net		Period		Amount		Amortization		Net		Period		Amount		Amortization		Net		Period
Non-compete agreements and other(a)	$	189,073	$	(165,712)	$	23,361	3	years	$	186,183	$	(163,575)	$	22,608	3	years	$	195,238	$	(174,573)	$	20,665	3	years	$	193,916	$	(172,618)	$	21,298	3	years
Prescription files		957,073		(875,955)		81,118	3	years		950,887		(867,430)		83,457	3	years		1,025,975		(907,329)		118,646	6	years		1,023,200		(900,321)		122,879	6	years
Customer relationships(a)		388,000		(239,848)		148,152	11	years		388,000		(231,015)		156,985	12	years		388,000		(268,674)		119,326	10	years		388,000		(261,584)		126,416	11	years
CMS license		57,500		(11,346)		46,154	20	years		57,500		(10,772)		46,728	21	years		57,500		(13,646)		43,854	19	years		57,500		(13,072)		44,428	20	years
Claims adjudication and other developed software		58,985		(41,566)		17,419	2	years		58,985		(39,459)		19,526	3	years		58,985		(49,994)		8,991	1	years		58,985		(47,887)		11,098	2	years
Trademarks		—		—		—	0	years		20,100		(9,413)		10,687	6	years
Backlog		11,500		(11,500)		—	0	years		11,500		(11,500)		—	0	years		11,500		(11,500)		—	0	years		11,500		(11,500)		—	0	years
Total finite	$	1,662,131	$	(1,345,927)		316,204			$	1,673,155	$	(1,333,164)	$	339,991			$	1,737,198	$	(1,425,716)		311,482			$	1,733,101	$	(1,406,982)	$	326,119
Trademarks		—		—		—	Indefinite			19,500		—		19,500	Indefinite			14,400		—		14,400	Indefinite			14,400		—		14,400	Indefinite
Total	$	1,662,131	$	(1,345,927)	$	316,204			$	1,692,655	$	(1,333,164)	$	359,491			$	1,751,598	$	(1,425,716)	$	325,882			$	1,747,501	$	(1,406,982)	$	340,519

(a)	Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

In connection with the RxEvolution initiatives previously announced on March 16, 2020, the Company ~~is in process of rebranding~~rebranded its EnvisionRxOptions and MedTrak subsidiaries to its new brand name, Elixir. These trademarks qualify as Level 3 within the fair value hierarchy. Upon the implementation of the rebranding initiatives during the first quarter of fiscal 2021, the Company has determined that the carrying value exceeded the fair value and consequently the Company incurred an impairment charge of $29,852 for these trademarks, which is included within intangible asset impairment charges within the condensed consolidated statement of operations.

Amortization expense for these intangible assets and liabilities was $20,460 and $24,420 ~~and $27,660~~ for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. The anticipated annual amortization expense for these intangible assets and liabilities is ~~2021—$84,368;~~ 2022—$~~63,491;~~73,637; 2023—$~~48,303;~~58,620; 2024—$~~34,663~~44,936; 2025—$33,650 and ~~2025—~~2026—$~~23,402.~~23,045.

2225

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

~~11.~~12. Indebtedness and Credit Agreements

Following is a summary of indebtedness and lease financing obligations at May ~~30, 2020~~29, 2021 and February ~~29, 2020:~~27, 2021:


	May 30,		February 29,		May 29,		February 27,
	2020		2020		2021		2021
Secured Debt:
Senior secured revolving credit facility due December 2023 ($892,000 and $650,000 face value less unamortized debt issuance costs of $17,901 and $19,167)	$	874,099	$	630,833
FILO term loan due December 2023 ($450,000 face value less unamortized debt issuance costs of $2,842 and $3,046)		447,158		446,954
Senior secured revolving credit facility due December 2023 ($889,000 and $850,000 face value less unamortized debt issuance costs of $12,837 and $14,103)					$	876,163	$	835,897
FILO term loan due December 2023 ($450,000 face value less unamortized debt issuance costs of $2,026 and $2,230)						447,974		447,770
		1,321,257		1,077,787		1,324,137		1,283,667
Second Lien Secured Debt:
7.5% senior notes due July 2025 ($600,000 face value less unamortized debt issuance costs of $10,414 and $10,927)		589,586		589,073
7.5% senior notes due July 2025 ($600,000 face value less unamortized debt issuance costs of $8,363 and $8,876)						591,637		591,124
8.0% senior notes due November 2026 ($849,918 face value less unamortized debt issuance costs of $16,707 and $17,477)						833,211		832,441
		589,586		589,073		1,424,848		1,423,565
Guaranteed Unsecured Debt:
6.125% senior notes due April 2023 ($1,153,490 face value less unamortized debt issuance costs of $7,745 and $8,430)		1,145,745		1,145,060
6.125% senior notes due April 2023 ($0 and $90,808 face value less unamortized debt issuance costs of $0 and $448)						—		90,360
		1,145,745		1,145,060		—		90,360
Unguaranteed Unsecured Debt:
7.70% notes due February 2027 ($237,386 face value less unamortized debt issuance costs of $876 and $908)		236,510		236,478
6.875% fixed-rate senior notes due December 2028 ($29,001 face value less unamortized debt issuance costs of $127 and $131)		28,874		28,870
7.70% notes due February 2027 ($237,386 face value less unamortized debt issuance costs of $742 and $776)						236,644		236,610
6.875% fixed-rate senior notes due December 2028 ($29,001 face value less unamortized debt issuance costs of $113 and $116)						28,888		28,885
		265,384		265,348		265,532		265,495
Lease financing obligations		26,656		28,166		23,423		23,120
Total debt		3,348,628		3,105,434		3,037,940		3,086,207
Current maturities of long-term debt and lease financing obligations		(8,066)		(8,840)		(7,261)		(6,409)
Long-term debt and lease financing obligations, less current maturities	$	3,340,562	$	3,096,594	$	3,030,679	$	3,079,798

Credit Facility

On December 20, 2018, the Company entered into a senior secured credit agreement (as amended by the First Amendment to Credit Agreement, dated as of January 6, 2020, the “Credit Agreement”), consisting of a $2,700,000 senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a $450,000 “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan,” and together with the Senior Secured Revolving Credit Facility, collectively, the “Existing Facilities”). The Company used proceeds from the Existing Facilities to refinance its prior $2,700,000 existing credit agreement (the “Old Facility”). The Existing Facilities extend the Company’s debt maturity profile and provide additional liquidity. Borrowings under the Senior Secured Revolving Credit Facility bear interest at a rate per annum between LIBOR plus 1.25% and LIBOR plus 1.75% based upon the

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Average ABL Availability (as defined in the Credit Agreement). Borrowings under the Senior Secured Term Loan bear interest at a rate per annum of LIBOR plus 3.00%. The Company is required to pay fees between 0.250% and 0.375%

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

per annum on the daily unused amount of the commitments under the Senior Secured Revolving Credit Facility, depending on Average ABL Availability. The Existing Facilities mature on December 20, 2023, subject to an earlier maturity on December 31, 2022 if the Company has not repaid or refinanced its existing 6.125% Senior Notes due 2023 (the “6.125% Notes”) prior to such date. The Company continues to take efforts to refinance its existing 6.125% Notes and intends to refinance or repay such notes prior to the early maturity becoming effective, although the Company cannot assure what impact the recent disruption in the financial markets will have on any such efforts.2023.

The Company’s borrowing capacity under the Senior Secured Revolving Credit Facility is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At May ~~30, 2020,~~29, 2021, the Company had ~~$1,342,000~~$1,339,000 of borrowings outstanding under the Existing Facilities and had letters of credit outstanding against the Senior Secured Revolving Credit Facility of ~~$102,939~~$122,023 which resulted in additional borrowing capacity under the Senior Secured Revolving Credit Facility of ~~$1,705,061.~~$1,688,977. If at any time the total credit exposure outstanding under the Existing Facilities and the principal amount of our other senior obligations exceed the borrowing base, the Company will be required to make certain other mandatory prepayments to eliminate such shortfall.

The Credit Agreement restricts the Company and all of its subsidiaries that guarantee its obligations under the Existing Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the “Subsidiary Guarantors”) from accumulating cash on hand in excess of $200,000 at any time when revolving loans are outstanding (not including cash located in store and lockbox deposit accounts and cash necessary to cover current liabilities). The Credit Agreement also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under the Existing Facilities or (ii) the sum of the Company’s borrowing capacity under the Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a “cash sweep period”), the funds in the Company’s deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Existing Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of the Existing Facilities.

With the exception of EI, substantially all of Rite Aid Corporation’s 100% owned subsidiaries guarantee the obligations under the Existing Facilities, the secured guaranteed notes and unsecured guaranteed notes. The Company’s obligations under the Existing Facilities and the Subsidiary Guarantors’ obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the “ABL priority collateral”) and (ii) a second-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations. The subsidiary guarantees related to the Company’s Existing Facilities, the secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Other than EI, the subsidiaries, including joint ventures, that do not guarantee the Existing Facilities and applicable notes, are minor.

The Credit Agreement allows the Company to have outstanding, at any time, up to an aggregate principal amount of $1,500,000 in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

in addition to borrowings under the Existing Facilities and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Credit Agreement) (excluding bridge facilities allowing extensions on

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

customary terms to at least the date that is 90 days after such date). Subject to the limitations described in clauses (i) and (ii) of the immediately preceding sentence, the Credit Agreement additionally allows the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Credit Agreement) is not in effect; provided, however, that certain of the Company’s other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Credit Agreement also contains certain restrictions on the amount of secured first priority debt the Company is able to incur. The Credit Agreement also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Existing Facilities are not in default and the Company maintains availability under its revolver of more than $365,000.

The Credit Agreement has a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Senior Secured Revolving Credit Facility is less than $200,000 or (ii) on the third consecutive business day on which availability under the Senior Secured Revolving Credit Facility is less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250,000. As of May ~~30, 2020,~~29, 2021, the Company’s fixed charge coverage ratio was greater than 1.00 to 1.00, and the Company was in compliance with the Credit Agreement’s financial covenant. The Credit Agreement also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.

The Credit Agreement provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if the Company fails to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment, repurchase, redemption or defeasance of such debt.

~~With the exception of EIC, substantially all of Rite Aid Corporation’s 100 % owned subsidiaries guarantee the obligations under the Existing Facilities, the secured guaranteed notes~~Fiscal 2020, 2021 and unsecured guaranteed notes. The Company’s obligations under the Existing Facilities and the Subsidiary Guarantors’ obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the “ABL priority collateral”) and (ii) a second-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations. The subsidiary guarantees related to the Company’s Existing Facilities, the secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Other than EIC, the subsidiaries, including joint ventures, that do not guarantee the Existing Facilities and applicable notes, are minor.

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

~~Fiscal 2019 and 2020~~2022 Transactions

On March 13, 2018, the Company issued a notice of redemption for all of the 9.25% Senior Notes due 2020 (the “9.25% Notes”) that were outstanding on April 12, 2018, pursuant to the terms of the indenture of the 9.25% Notes. On April 12, 2018, the Company redeemed 100% of the outstanding 9.25% Notes. In connection therewith, the Company recorded a loss on debt retirement of $3,422 which included unamortized debt issuance costs, partially offset by unamortized discount. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On April 19, 2018, the Company announced that it had commenced an offer to purchase up to $700,000 of its outstanding 6.75% Senior Notes due 2021 (the “6.75% Notes”) and its 6.125% Notes pursuant to the asset sale provisions of such indentures. On May 21, 2018, the Company accepted for payment, pursuant to its offer to purchase, $1,360 aggregate principal amount of the 6.75% Notes and $4,759 aggregate principal amount of the 6.125% Notes. The debt repayment and related loss on debt retirement of $8 for the 6.75% Notes is included in the results of operations and cash flows of discontinued operations. The debt repayment and related loss on debt retirement of $56 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations.

On April 29, 2018, the Company further reduced the borrowing capacity on its Old Facility from $3,000,000 to $2,700,000. In connection therewith, the Company recorded a loss on debt retirement of $1,091, which included unamortized debt issuance costs. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On June 25, 2018, the Company redeemed the remaining $805,169 of its 6.75% Notes, which resulted in a loss on debt retirement of $18,075. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On October 11, 2019, the Company completed a privately negotiated purchase from a noteholder and its affiliated funds of $84,097 aggregate principal amount of the 7.70% Notes due 2027 (the “7.70% Notes”) and 6.875% fixed-rate Senior Notes due 2028 (the “6.875% Notes”) for $51,300. In connection therewith, the Company recorded a gain on debt retirement of $32,416, which included unamortized debt issuance costs. The debt repayment and related gain on debt retirement is included in the results of operations and cash flows of continuing operations.

On October 15, 2019, the Company commenced an offer to purchase up to $100,000 of its outstanding 7.70% Notes and its 6.875% Notes. In November 2019, the Company accepted for payment $18,075 aggregate principal amount of the 7.70% Notes and $39,441 aggregate principal amount of the 6.875% Notes for $38,392. In connection therewith, the Company recorded a gain on debt retirement of $18,510, which included unamortized debt issuance costs. The debt repayment and related gain on debt retirement is included in the results of operations and cash flows of continuing operations.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

During November 2019, the Company made additional purchases of $15,000 aggregate principal amount of the 7.70% Notes for $10,012. In connection therewith, the Company recorded a gain on debt retirement of $4,766, which included unamortized debt issuance costs. The debt repayment and related gain on debt retirement is included in the results of operations and cash flows of continuing operations.

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

On January 6, 2020, the Company commenced an offer to exchange up to $600,000 aggregate principal amount of the outstanding 6.125% Notes for newly issued 7.500% Senior Secured Notes due 2025 (the “7.500% Notes”). On February 5, 2020, the Company announced that the exchange offer was oversubscribed and accepted for payment $600,000 aggregate principal amount of the 6.125% Notes in exchange for newly issued 7.500% Notes. The Company accounted for the exchange as a debt modification and accordingly did not record a loss on debt retirement.

The 7.500% Notes mature on July 1, 2025, and are guaranteed on a senior secured basis by the same Subsidiary Guarantors that guarantee the Existing Facilities and the 6.125% Notes. The 7.500% Notes and the obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and other collateral to the extent it does not constitute ABL priority collateral (as defined below), and (ii) a second-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivables, payment intangibles, inventory, prescription files (including eligible script lists) and, intellectual property (prior to the repayment of the Senior Secured Term Loan (collectively, the “ABL priority collateral”), which, in each case, also secure the Existing Facilities.

On June 25, 2020, the Company commenced an offer to exchange (the “June 25, 2020 Exchange Offer”) up to $750,000 aggregate principal amount of the outstanding 6.125% Notes for a combination of $600,000 newly issued 8.0% Senior Secured Notes due 2026 (the “8.0% Notes”) and $145,500 cash. ~~The~~On July 10, 2020, the Company ~~anticipates~~increased the maximum amount of 6.125% Notes that may be accepted for exchange from $750,000 to $1,125,000 and, on July 24, 2020, the Company announced that it accepted for payment $1,062,682 aggregate principal amount of the 6.125% Notes in exchange ~~will be considered~~for $849,918 aggregate principal amount of newly issued 8.0% Notes and $206,373 in cash. In connection therewith, the Company recorded a gain on debt modification of $5,274 which is included in the results of operations and ~~accordingly, anticipates a minimal loss on the exchange during the second quarter~~cash flows of ~~fiscal 2021.~~continuing operations. The 8.0% Notes ~~will be~~are secured on an equal and ratable basis by the same assets that secure the 7.500% Notes. The 8.0% Notes ~~will be~~are guaranteed on a senior secured basis by the same subsidiaries that guarantee the 7.500% Notes. In conjunction with the June 25, 2020 Exchange Offer, the Company also commenced a solicitation of consents from the holders of outstanding 6.125% Notes to certain proposed amendments to the indenture governing the 6.125% ~~Notes,~~Notes. On July 9, 2020, following the receipt of the requisite number of consents, the Company entered into a supplemental indenture, which ~~would modify~~modified certain limitations in the debt covenant to allow for the creation of the 8.0% Notes.

On April 28, 2021, the Company issued a notice of redemption for all of the 6.125% Notes that were outstanding on May 28, 2021, pursuant to the terms of the indenture of the 6.125% Notes. On May 28, 2021, the Company redeemed 100% of the remaining outstanding 6.125% Notes at par. In connection therewith, the Company recorded a loss on debt retirement of $396 which included unamortized debt issuance costs. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of continuing operations.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Maturities

The aggregate annual principal payments of long-term debt for the remainder of fiscal ~~2021~~2022 and thereafter are as follows: ~~2021—$0;~~ 2022—$0; 2023—$0; 2024—$~~2,495,490;~~1,339,000; 2025—$00; 2026—$600,000 and $866,387 thereafter (without giving effect to the June 25, 2020 Exchange Offer). These aggregate annual principal payments of long-term debt assume that the Company has repaid or refinanced its existing 6.125% Notes prior to December 31, 2022.$1,116,305 thereafter.

~~12.~~13. Leases

The Company leases most of its retail stores and certain distribution facilities under noncancelable operating and finance leases, most of which have initial lease terms ranging from 5 to 22 years. The Company also leases certain of its equipment and other assets under noncancelable operating leases with initial terms ranging from 3 to 10 years. In addition to minimum rental payments, certain store leases require additional payments based on sales volume, as well as reimbursements for taxes, maintenance and insurance. Most leases contain renewal options, certain of which involve rent increases.

The following table is a summary of the Company’s components of net lease cost for the thirteen week periods ended May 29, 2021 and May 30, 2020:


	Thirteen Week Period Ended
	May 29, 2021		May 30, 2020
Operating lease cost	$	169,494	$	161,866
Financing lease cost:
Amortization of right-of-use asset		1,011		1,131
Interest on long-term finance lease liabilities		568		689
Total finance lease costs	$	1,579	$	1,820
Short-term lease costs		1,099		153
Variable lease costs		46,038		42,448
Less: sublease income		(3,343)		(4,132)
Net lease cost	$	214,867	$	202,155

Supplemental cash flow information related to leases for the thirteen week periods ended May 29, 2021 and May 30, 2020:


	Thirteen Week Period Ended
	May 29, 2021		May 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases	$	176,591	$	170,370
Operating cash flows paid for interest portion of finance leases		568		689
Financing cash flows paid for principal portion of finance leases		1,111		1,243
Right-of-use assets obtained in exchange for lease obligations:
Operating leases		76,314		107,913
Finance leases		0		0

2730

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May ~~30, 2020~~29, 2021 and ~~June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

~~The following table is a summary of the Company’s components of net lease cost for the~~ ~~thirteen week~~ ~~periods ended~~ May 30, 2020 ~~and June 1, 2019:~~

Thirteen Week Period Ended

May 30, 2020

June 1, 2019

Operating lease cost

$
161,866

$
164,983

Financing lease cost:

Amortization of right-of-use asset

1,131

1,536

Interest on long-term finance lease liabilities

689

905

Total finance lease costs

$
1,820

$
2,441

Short-term lease costs

153

1

Variable lease costs

42,448

40,545

Less: sublease income

(4,132)

(5,751)

Net lease cost

$
202,155

$
202,219

~~Supplemental cash flow information related to leases for the thirteen week periods ended May 30, 2020 and June 1, 2019:~~

Thirteen Week Period Ended

May 30, 2020

June 1, 2019

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows paid for operating leases

$
170,370

$
176,237

Operating cash flows paid for interest portion of finance leases

689

905

Financing cash flows paid for principal portion of finance leases

1,243

3,490

Right-of-use assets obtained in exchange for lease obligations:

Operating leases

107,913

77,384

Finance leases

—

—

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Supplemental balance sheet information related to leases as of May ~~30, 2020~~29, 2021 and February ~~29, 2020~~27, 2021 (in thousands, except lease term and discount rate):


	May 30,			February 29,			May 29,			February 27,
	2020			2020			2021			2021
Operating leases:
Operating lease right-of-use asset	$	2,894,333		$	2,903,256		$	3,013,577		$	3,064,077

Short-term operating lease liabilities	$	490,202		$	490,161		$	517,602		$	516,752
Long-term operating lease liabilities		2,694,929			2,710,347			2,771,797			2,829,293
Total operating lease liabilities	$	3,185,131		$	3,200,508		$	3,289,399		$	3,346,045

Finance leases:
Property, plant and equipment, net	$	18,533		$	19,904		$	16,506		$	16,074

Current maturities of long-term debt and lease financing obligations	$	8,066		$	8,840		$	7,261		$	6,409
Lease financing obligations, less current maturities		18,590			19,326			16,162			16,711
Total finance lease liabilities	$	26,656		$	28,166		$	23,423		$	23,120
Weighted average remaining lease term
Operating leases		7.7			7.8			7.8			7.9
Finance leases		9.0			8.9			8.4			8.9

Weighted average discount rate
Operating leases		6.1	%		6.1	%		6.0	%		6.0	%
Finance leases		10.4	%		10.2	%		10.1	%		9.8	%

The following table summarizes the maturity of lease liabilities under finance and operating leases as of May ~~30, 2020:~~29, 2021:


	May 30, 2020						May 29, 2021
	Finance		Operating				Finance		Operating
Fiscal year	Leases		Leases (1)		Total		Leases		Leases (1)		Total
2021 (remaining thirty-nine weeks)	$	10,225	$	500,821	$	511,046
2022		4,078		625,642		629,720
2022(remaining thirty-nine weeks)							$	7,868	$	522,553	$	530,421
2023		3,876		573,793		577,669		4,953		660,310		665,263
2024		3,597		512,399		515,996		3,390		599,834		603,224
2025		3,280		414,314		417,594		3,149		502,915		506,064
2026								2,367		410,090		412,457
Thereafter		15,914		1,382,115		1,398,029		13,548		1,441,967		1,455,515
Total lease payments		40,970		4,009,084		4,050,054		35,275		4,137,669		4,172,944
Less: imputed interest		(14,314)		(823,953)		(838,267)		(11,852)		(848,270)		(860,122)
Total lease liabilities	$	26,656	$	3,185,131	$	3,211,787	$	23,423	$	3,289,399	$	3,312,822

(1)	– Future operating lease payments have not been reduced by minimum sublease rentals of ~~$44~~$39 million due in the future under noncancelable leases.

2931

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

During the thirteen week ~~periods~~period ended May 29, 2021, the Company sold 2 owned and operating stores to independent third parties. Net proceeds from the sales were $7,456 for the thirteen week period ended May 29, 2021. Concurrent with these sales, the Company entered into agreements to lease the properties back from the purchasers over a minimum lease term of 15 years. The Company accounted for these leases as operating lease right-of-use assets and corresponding operating lease liabilities in accordance with the Lease Standard. The transaction resulted in a gain of $3,688 which is included in the gain on sale of assets, net for the thirteen week period ended May 29, 2021. During the thirteen week period ended May 30, 2020 ~~and~~ ~~June 1, 2019~~, the Company did not enter into any sale-leaseback ~~transactions whereby the~~transactions. The Company ~~sold owned operating stores~~has additional capacity under its outstanding debt agreements to ~~independent third parties and concurrent with the sale, entered~~enter into ~~an agreement to lease the store back from the purchasers.~~additional sale-leaseback transactions.

~~13.~~14. Retirement Plans

Net periodic pension expense for the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and~~ ~~June 1, 2019~~, for the Company’s defined benefit plan includes the following components:


	Defined Benefit				Defined Benefit
	Pension Plan				Pension Plan
	Thirteen Week Period Ended				Thirteen Week Period Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
Service cost	$	144	$	143	$	128	$	144
Interest cost		1,199		1,556		1,232		1,199
Expected return on plan assets		(1,177)		(1,214)		(1,313)		(1,177)
Amortization of unrecognized net loss		911		415		123		911
Net periodic pension expense	$	1,077	$	900	$	170	$	1,077

During the thirteen week period ended May ~~30, 2020~~29, 2021 the Company contributed $0$805 to the Defined Benefit Pension Plan. During the remainder of fiscal ~~2021,~~2022, the Company expects to contribute ~~$6,330~~$3,040 to the Defined Benefit Pension Plan.

~~14.~~15. Segment Reporting

The Company has 2 reportable segments, its retail drug stores (“Retail Pharmacy”), and its pharmacy services (“Pharmacy Services”) segments.

The Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of pharmacy benefit management services including plan design and administration, ~~on both a transparent pass-through model and traditional model,~~ formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, ~~infertility treatment,~~ and drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.

The Company’s chief operating decision makers are its Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, ~~and the President—Pharmacy Services,~~ (collectively the “CODM”). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management

3032

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit, and Adjusted EBITDA.

The following is balance sheet information for the Company’s reportable segments:


	Retail		Pharmacy						Retail		Pharmacy
	Pharmacy		Services		Eliminations(1)		Consolidated		Pharmacy		Services		Eliminations(1)		Consolidated
May 30, 2020:
May 29, 2021:
Total Assets	$	6,815,598	$	2,721,741	$	(16,465)	$	9,520,874	$	6,561,475	$	2,803,665	$	(13,694)	$	9,351,446
Goodwill		43,492		1,064,644		—		1,108,136		43,492		1,064,644		—		1,108,136
February 29, 2020:
February 27, 2021:
Total Assets	$	6,757,196	$	2,709,737	$	(14,564)	$	9,452,369	$	6,613,370	$	2,736,546	$	(14,512)	$	9,335,404
Goodwill		43,492		1,064,644		—		1,108,136		43,492		1,064,644		—		1,108,136

(1)

As of May ~~30, 2020~~29, 2021 and February ~~29, 2020,~~27, 2021, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $0 against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of ~~$16,465~~$13,694 and ~~$14,564,~~$14,512, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

The following table is a reconciliation of the Company’s business segments to the consolidated financial statements for the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and~~ ~~June 1, 2019~~:


	Retail		Pharmacy		Intersegment				Retail		Pharmacy		Intersegment
	Pharmacy		Services		Eliminations(1)		Consolidated		Pharmacy		Services		Eliminations(1)		Consolidated
Thirteen Week Period Ended
May 29, 2021:
Revenues									$	4,351,682	$	1,872,282	$	(62,979)	$	6,160,985
Gross Profit										1,169,934		114,941		—		1,284,875
Adjusted EBITDA(2)										94,914		43,963		—		138,877
Additions to property and equipment and intangible assets										60,893		3,707		—		64,600
May 30, 2020:
Revenues	$	4,123,271	$	1,977,246	$	(73,141)	$	6,027,376	$	4,123,271	$	1,977,246	$	(73,141)	$	6,027,376
Gross Profit		1,081,536		116,783		—		1,198,319		1,081,536		116,783		—		1,198,319
Adjusted EBITDA(2)		62,982		44,410		—		107,392		62,982		44,410		—		107,392
Additions to property and equipment and intangible assets		36,607		2,567		—		39,174		36,607		2,567		—		39,174
June 1, 2019:
Revenues	$	3,864,808	$	1,566,292	$	(58,511)	$	5,372,589
Gross Profit		1,030,495		96,228		—		1,126,723
Adjusted EBITDA(2)		84,008		26,339		—		110,347
Additions to property and equipment and intangible assets		44,244		4,947		—		49,191

(1)

Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

3133

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

(2)	See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details.

The following is a reconciliation of net income (loss) to Adjusted EBITDA for the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and~~ ~~June 1, 2019~~:


	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020
	(13 weeks)		(13 weeks)		(13 weeks)		(13 weeks)
Net loss from continuing operations	$	(72,702)	$	(99,339)	$	(13,057)	$	(72,702)
Interest expense		50,547		58,270		49,121		50,547
Income tax (benefit) expense		(8,018)		7,374
Income tax expense (benefit)						780		(8,018)
Depreciation and amortization		79,103		83,926		75,859		79,103
LIFO (credit) charge		(12,066)		7,489
Lease termination and impairment charges		3,753		478
LIFO credit						(3,993)		(12,066)
Facility exit and impairment charges						8,831		3,753
Intangible asset impairment charges		29,852		—		—		29,852
Loss on debt retirements, net						396		—
Merger and Acquisition-related costs		—		3,085		3,886		—
Stock-based compensation expense		1,874		5,380		2,811		1,874
Restructuring-related costs		35,735		43,350		5,932		35,735
Inventory write-downs related to store closings		834		841		472		834
Litigation settlements						14,000		—
Gain on sale of assets, net		(2,260)		(2,712)		(6,558)		(2,260)
Other		740		2,205		397		740
Adjusted EBITDA from continuing operations	$	107,392	$	110,347	$	138,877	$	107,392

~~15.~~16. Commitments, Contingencies and Guarantees

Legal Matters and Regulatory Proceedings

The Company is regularly involved in ~~numerous~~a variety of legal matters including arbitration, litigation ~~arbitration,~~(and related settlement discussions), and other claims, and is subject to regulatory proceedings including ~~investigations,~~audits, inspections, ~~audits,~~ inquiries, investigations, and similar actions by ~~pharmacy,~~ health care, insurance, pharmacy, tax and other governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss has been incurred, and the amount can be reasonably estimated. The Company evaluates on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual ~~and developments~~or that ~~would make a loss contingency both probable and reasonably estimable, and as a result,~~ warrant an accrual. If a loss contingency is not both probable and estimable, the Company typically does not establish an accrued liability. ~~None of the Company’s accruals for outstanding legal matters or regulatory proceedings are material individually or in the aggregate~~With respect to the ~~Company’s consolidated financial position.~~

~~The Company’s contingencies are subject~~litigation and other legal proceedings described below, the Company is unable to ~~significant uncertainties, many~~estimate the amount or range of ~~which are beyond~~reasonably possible loss due to the ~~Company’s control, including, among other factors: (i) proceedings are in early stages; (ii) whether class or collective action status is sought and the likelihood~~inherent difficulty of ~~a class being certified; (iii)~~predicting the outcome of ~~pending appeals or motions;~~and uncertainties regarding such litigation and legal proceedings.

3234

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

None of the Company’s accruals for outstanding legal matters or regulatory proceedings are currently material, individually or in the aggregate, to the Company’s consolidated financial position. However, during the course of any proceeding, developments may result in the creation or an increase of an accrual that could be material. Additionally, unfavorable or unexpected outcomes in outstanding legal matters or regulatory proceedings could exceed any accrual and impact the Company’s financial position. Further, even if the Company is successful in its legal proceedings, the Company may incur significant costs and expenses defending itself or others that it is required to indemnify, and such costs and expenses may not be subject to or exceed reimbursement pursuant to any applicable insurance.

The Company’s contingencies are subject to significant uncertainties, many of which are beyond the Company’s control, including, among other factors: (i) the stage of any proceeding and delays in scheduling; (ii) whether class or collective action status is sought and the likelihood of a class being certified; (iii) the outcome of pending or potential appeals, motions and settlement discussions; (iv) the ~~extent~~range and magnitude of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at ~~issue;~~issue or advanced; (vii) whether there are significant factual issues to be resolved; ~~and/or~~ (viii) in the case of certain government agency investigations, whether a qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following ~~investigation. While~~investigation, and/or (viii) changes in priorities following any change in political administration at the ~~Company cannot predict the outcome of any of the contingencies, the Company’s management does not believe that the outcome of any of these legal matters~~state or regulatory proceedings will be material to the Company’s consolidated financial position. It is possible, however, the Company’s results of operations or cash flows could be materially affected by unfavorable outcomes in outstanding legal matters or regulatory proceedings.federal level.

California Employment Litigation.

The Company is currently a defendant in several lawsuits filed in courts in California that contain allegations regarding violations of the California Business and Professions Code, various California employment laws and regulations, industry wage orders, wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay premiums for missed meals and rest periods, failure to provide accurate wage statements, and failure to reimburse business expenses (the “California Cases”). Some of the California Cases purport or may be determined to be class actions or ~~PAGA~~ representative actions under the California Private Attorneys General Act and seek substantial damages and penalties. These single-plaintiff and multi-plaintiff California Cases in the aggregate, seek substantial damages. In June 2021, the Company agreed to settle 2 of the California Cases in which the plaintiffs brought class-based claims alleging that they and all other similarly-situated associates were not paid for time waiting for their bags to be checked. One set of cases involving store associates was settled for $9,000, while the other involving distribution center associates was settled for $1,750. As class actions, both settlements must be approved by the court. The Company believes that ~~its~~it has meritorious defenses ~~and assertions~~ in the California ~~Cases have merit.~~Cases. The Company has aggressively defended itself and challenged the merits of the lawsuits and, where applicable, allegations that the lawsuits should be certified as class or representative actions. ~~Additionally, at this time the~~

Usual and Customary Litigation.

The Company is named as a defendant in a number of lawsuits, including the cases below, that allege that the Company’s retail stores overcharged for prescription drugs by not ~~able~~submitting the price available to ~~predict either~~members of the ~~outcome of or estimate a potential range of loss with respect to~~Rite Aid’s Rx Savings Program as the ~~California Cases~~pharmacy’s usual and customary price, and related theories. The Company is defending itself against these ~~claims~~

~~Usual and Customary and DUR/Code 1 Litigation.~~claims.

In January 2017, qui tam plaintiff Azam Rahimi (“Relator”) filed a sealed False Claims Act (“FCA”) lawsuit in the United States District Court for the Eastern District of Michigan. The United States Attorney’s Office for the Eastern

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020

(Dollars and share information in thousands, except per share amounts)

(unaudited)

District of Michigan, 18 states, and the District of Columbia declined to intervene. The unsealed lawsuit alleges that the Company failed to report ~~Rite Aid’s~~its Rx Savings Program prices as its usual and customary ~~charges~~prices under the Medicare Part D program, federal and state Medicaid programs, and other publicly funded health care programs, and that the Company is thus liable under the federal FCA and similar state statutes. On December 12, 2019, the court granted the Company’s motion to dismiss and judgment on the pleadings based upon the FCA’s public disclosure bar. The Relator filed a motion for reconsideration which was denied. The Relator has appealed from the order granting the Company’s motion to dismiss and for judgment on the pleadings, and also from the order denying his motion for reconsideration. ~~At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit~~That appeal has been fully argued and briefed and is ~~defending itself against these claims.~~now awaiting decision.

The State of Mississippi, by and through its Attorney General, filed a lawsuit against the Company and various purported related entities on September 27, 2016 alleging the Company failed to accurately report usual and customary prices to Mississippi’s Division of Medicaid. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit, and is defending itself against these claims.

~~Table of Contents~~

~~RITE AID CORPORATION AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~For the Thirteen Week Periods Ended May 30, 2020 and June 1, 2019~~

~~(Dollars and share information in thousands, except per share amounts)~~

~~(unaudited)~~

The Company is involved in a putative consumer class action lawsuit in the United States District Court for the Southern District of California captioned Byron Stafford v. Rite Aid Corp. A separate lawsuit, Robert Josten v. Rite Aid Corp., was consolidated with this lawsuit in November, 2019. The lawsuit contains allegations that (i) the Company was obligated to charge the plaintiffs’ insurance companies ~~a “usual~~its usual and ~~customary” price~~customary prices for their prescription drugs; and (ii) the Company failed to do so because the prices it reported were not equal to or adjusted to account for the prices that Rite Aid offers to uninsured and underinsured customers through its Rx Savings Program. ~~At this stage~~The cases are currently stayed pending an appeal of ~~the proceedings, the Company is not able~~an order denying a motion to ~~either predict the outcome or estimate a potential range~~compel arbitration of ~~loss and is defending itself against these claims.~~claims in Stafford.

On February 6, 2019, Humana, ~~Inc,~~Inc., filed an arbitration claim alleging that the Company improperly submitted various usual and customary overcharges by failing to report its Rx Savings Program prices as its usual and customary prices to Humana. An arbitral hearing is scheduled to commence in September 2021.

The Company is a defendant in 2 consolidated lawsuits pending in the United States District Court for the District of Minnesota filed in 2020 by various Blue Cross/Blue Shield plans that operate in 8 different states (North Carolina, North Dakota, Alabama, Utah, Minnesota, Oregon, Washington and New Jersey) alleging that the Company improperly submitted various usual and customary overcharges by failing to report its Rx Savings Program pricing to ~~Humana. At this stage of~~several Pharmacy Benefit Managers with which Rite Aid and the ~~proceedings,~~insurers had independent contracts.

Drug Utilization Review and Code 1 Litigation

In June 2012, qui tam plaintiff, Loyd F. Schmuckley (“Relator”) filed a complaint under seal against the Company ~~is not able~~alleging that it failed to ~~either predict the outcome~~comply with certain requirements of ~~this arbitration proceeding or estimate a potential range of loss,~~California’s Medicaid program between 2007 and ~~is defending itself against these claims.~~

2014. In June 2013, the Company was served with a Civil Investigative Demand (“CID”) by the United States Attorney’s Office for the Eastern District of California ~~(the “USAO”)~~ regarding (1) the Company’s Drug Utilization Review ~~(“DUR”)~~ and prescription dispensing protocol; and (2) the dispensing of drugs designated as “Code 1” by the State of California. Specifically, the Relator alleged that the Company did not perform special verification and documentation for certain medications known as “Code 1” drugs. While the complaint remained under seal, the United States Department of Justice conducted an extensive investigation and ultimately declined to intervene. Although numerous states declined to intervene, in September 2017, the State of California filed a complaint in intervention. The Company ~~cooperated with the investigation, researched the government’s allegations, and refuted the government’s position. The Company produced documents including certain prescription files related~~filed a motion to ~~Code 1 drugs to the USAO’s office~~dismiss Relator’s and the State of California Department of Justice’s Bureau of Medical Fraud and Elder Abuse ~~(“CADOJ”). In August 2014, the USAO and 8 states’ attorneys general declined to intervene in a California False Claim Act lawsuit filed under seal in the Eastern District of California by~~ ~~qui tam~~ plaintiff Loyd F. Schmuckley (“Relator”) based on DUR and Code 1 allegations. In July 2016, the Commonwealth of Massachusetts and the District of Columbia also declined to intervene in the lawsuit. At this stage of the proceedings, the Company is not able to either predict the outcome of this matter or estimate a potential range of loss with respect to this matter, and is defending itself against these claims.

~~Controlled Substances Litigation, Audits and Investigations~~

The Company along with various other defendants are named in multiple opioid-related lawsuits filed by counties, cities, municipalities, Native American tribes, hospitals, third-party payers, and others across the United States. In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated and transferred hundreds of federal opioid-related lawsuits that name the Company and/or a related entity as a defendant to the multi-district litigation (“MDL”) pending in the United States District Court for the Northern District of Ohio before Judge Dan Polster under ~~In re National Prescription Opiate Litigation~~ (Case No. 17-MD-2804). A significant number of similar cases that are not part of the MDL and name the Company and/or a related entity or entities as a defendant in also are pending in state courts. The plaintiffs in all of these opioid-related lawsuits generally allege claims concerning the impacts of widespread opioid abuse against defendants along the pharmaceutical supply chain, including manufacturers, wholesale distributors, and retail pharmacies. At this stage of the proceedings, the Company is not able to predict the outcome of the opioid-related lawsuits or estimate a potential range of loss regarding the lawsuits. The Company is defending itself against all relevant claims.

3436

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

respective complaints in January 2018, the hearing was held on March 23, 2018. On September 5, 2018, the court issued an order denying the motion to dismiss. No trial date has been set.

Controlled Substances Litigation, Audits and Investigations

The Company, along with various other defendants, is named in multiple opioid-related lawsuits filed by counties, cities, municipalities, Native American tribes, hospitals, third-party payers, and others across the United States. In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated and transferred more than a thousand federal opioid-related lawsuits that name the Company as a defendant to the multi-district litigation (“MDL”) pending in the United States District Court for the Northern District of Ohio under In re National Prescription Opiate Litigation (Case No. 17-MD-2804). A significant number of similar cases that are not part of the MDL and name the Company as a defendant are also pending in state courts. The plaintiffs in these opioid-related lawsuits generally allege claims that include public nuisance and negligence theories of liability resulting from the impacts of widespread opioid abuse against defendants along the pharmaceutical supply chain, including manufacturers, wholesale distributors, and retail pharmacies.At this stage of the proceedings, the Company is not able to predict the outcome of the opioid-related lawsuits or estimate a potential range of loss regarding the lawsuits, and is defending itself against all relevant claims. From time to time, some of these cases may be settled, dismissed or otherwise terminated, and additional such cases may be filed.

The Company also has received warrants, subpoenas, CIDs, and other requests for documents and information from, and is being investigated by, the federal and state governments regarding opioids and other controlled substances. The Company has been cooperating with and responding to these investigatory inquiries.

In April 2019, the Company initiated a coverage action styled Rite Aid Corporation et al. v. ACE American Ins. Co. et al. Through this action, the Company is seeking the recovery of defense costs and future settlement and/or judgment costs for the opioid-related lawsuits. The action seeks declaratory relief with respect to the obligations of the insurers under all of the policies at issue in the action and asserts claims for breach of contract and statutory remedies against an insurer. While the Company prevailed on a partial summary judgment motion that this insurer has a past and continuing duty to reimburse defense costs for the suits in excess of a satisfied $3,000 retention, that insurer has appealed the ruling and has refused to reimburse the Company for any of its defense costs. The briefing on the insurer’s appeal has been submitted. The Delaware Supreme Court has not yet set a date of oral argument or alternatively a date for disposition without argument.

Miscellaneous Litigation and Investigations.

The U.S. Securities and Exchange Commission (“SEC”) is investigating trading in the Company’s securities that occurred in or around January 2017, and has subpoenaed information from the Company in connection with that investigation. The Company is cooperating with the SEC in this matter. In addition to the above described matters, the Company is subject from time to time to various claims and lawsuits and governmental investigations arising in the ordinary course of business. While the Company’s management cannot predict the outcome of any of the claims, the Company’s management does not believe that the outcome of any of these matters will be material to the Company’s consolidated financial position. It is possible, however, that the Company’s results of operations or cash flows could be materially affected by an unfavorable resolution of pending litigation or contingencies.

These other legal proceedings include claims of improper disclosure of personal information, anticompetitive practices, general contractual matters, product liability, professional malpractice, non-compliance with state and federal regulatory regimes, marketing misconduct, intellectual property litigation and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company ~~is defending itself against the claims brought in these matters.~~has received a CID and requests for information with respect to consumer protection laws.

~~16.~~~~Supplementary Cash Flow Data~~

Thirteen Week Period Ended

May 30, 2020

June 1, 2019

Cash paid for interest(a)

$
12,843

$
19,462

Cash payments for income taxes, net(a)

$
2,100

$
830

Equipment financed under capital leases

$
335

$
1,253

Gross borrowings from revolver(a)

$
2,139,000

$
499,000

Gross repayments to revolver(a)

$
1,897,000

$
374,000

~~(a)~~

~~— Amounts are presented on a total company basis.~~

~~Significant components of cash provided by Other Liabilities of $13,263 for the~~ ~~thirteen~~ ~~week period ended May 30, 2020 include cash provided from the employer payroll tax payment deferral under the CARES act of $26,308, partially offset by lower compensation and benefit related accruals.~~

~~17.~~~~Subsequent Events~~

The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business and the markets in which it operates, including how the pandemic will impact its customers, associates, suppliers, vendors, business partners and supply chain. Due to the significant amount of uncertainties that continue to exist relative to the pandemic, the Company is unable to predict the impact that COVID-19 will have on its financial position and results of operations, but such impact could be material.

3537

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~

(Dollars and share information in thousands, except per share amounts)

(unaudited)

17.Supplementary Cash Flow Data


	Thirteen Week Period Ended
	May 29, 2021		May 30, 2020
Cash paid for interest(a)	$	12,813	$	12,843
Cash payments for income taxes, net(a)	$	556	$	2,100
Equipment financed under capital leases	$	1,585	$	335
Gross borrowings from revolver(a)	$	1,546,000	$	2,139,000
Gross repayments to revolver(a)	$	1,507,000	$	1,897,000

(a)	— Amounts are presented on a total company basis.

AsA significant component of ~~June 25, 2020,~~cash provided by Other Liabilities of $34,559 for the ~~Company had liquidity~~thirteen week period ended May 29, 2021 includes cash provided from an increase in accrued interest of $1.7 billion, which consisted of availability to borrow under its Senior Secured Revolving Credit Facility of $1.5 billion and cash on hand of $180.0 million. The Company will continue to assess the impact of COVID-19 on the Company’s financial position. However, the extent to which the COVID-19 outbreak will impact the Company’s operations or financial results is uncertain, but such impact could be material.$33,211.

During late May 2020 and early June 2020, a period of civil unrest took place in certain markets in which the Company operates and some of the Company’s stores were damaged. As of July 2, 2020, the Company was still assessing damages and losses and some of such damaged stores remain closed. The Company maintains insurance coverage for inventory and property damage and also maintains business interruption insurance coverage. The Company does not believe that the damages and losses, net of insurance claim settlement proceeds, will have a material impact on the Company's financial position or results of operations in future periods.

3638

Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations

Overview

We are a healthcare company with a retail footprint, providing our customers and communities with a high level of care and service through various programs we offer through our two reportable business segments, our Retail Pharmacy segment and our Pharmacy Services segment. We accomplish our goal of delivering comprehensive care to our customers through our retail drugstores ~~RediClinic walk-in retail health clinics~~ and our ~~transparent and traditional PBMs, EnvisionRxOptions and MedTrak, soon to be rebranded~~PBM, Elixir. We also offer fully integrated mail-order and specialty pharmacy services through ~~EnvisionPharmacies.~~Elixir Pharmacy. Additionally, through ~~EIC, EnvisionRxOptions~~Elixir Insurance (“EI”), Elixir also serves one of the fastest-growing demographics in healthcare: seniors enrolled in Medicare Part D. When combined with our retail platform, this comprehensive suite of services allows us to provide value and choice to customers, patients and payors and allows us to compete in today's evolving healthcare marketplace.

Retail Pharmacy Segment

Our Retail Pharmacy segment sells brand and generic prescription drugs and various other pharmacy services, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a large private brand product line. Our Retail Pharmacy segment generates the majority of its revenue through the sale of prescription drugs and front-end products at our over ~~2,400~~2,500 retail pharmacy locations across 1817 states. We replenish our retail stores through a combination of direct store delivery of pharmaceutical products facilitated through our pharmaceutical Purchasing and Delivery Agreement with McKesson, and the majority of our front-end products through our network of distribution centers.

Pharmacy Services Segment

Our Pharmacy Services segment provides a full range of pharmacy benefit services through EnvisionRxOptions. The Pharmacy Services segment provides both transparent and traditional PBM options through its EnvisionRxOptions and MedTrak PBMs. EnvisionRxOptions also offers fully integrated ~~mail-order and~~suite of PBM offerings including technology solutions, mail delivery services, specialty pharmacy, ~~services through EnvisionPharmacies; an innovative~~network and rebate administration, claims adjudication ~~software platform in Laker Software;~~ and ~~a national~~pharmacy discount programs. Elixir also provides prescription discount programs and Medicare Part D ~~prescription drug plan through EIC’s EnvisionRx Plus product offering. The segment’s~~insurance offerings for individuals and groups. Elixir provides services to various clients ~~are primarily employers, insurance companies, unions, government employee groups,~~across its different lines of business, including major health plans, ~~Managed Medicaid~~commercial employers, labor groups and state and local governments, representing approximately 3.2 million covered lives, including approximately 1 million covered lives through our Medicare Part D insurance offerings. Elixir continues to focus its efforts and offerings to its target market of small to mid-market employers, labor unions and regional health plans, ~~Medicare plans, other sponsors of~~including provider-led health ~~benefit~~ plans and ~~individuals throughout the United States.~~

government sponsored Medicaid and Medicare plans.

Restructuring

Beginning in Fiscal 2019, we initiated a series of restructuring plans designed to reorganize our executive management team, reduce managerial layers, and consolidate roles. In March 2020, we announced the details of our RxEvolution strategy, which includes building tools to work with regional health plans to improve patient health outcomes, rationalizing SKU’s in our front-end offering to free up working capital and update our merchandise assortment, assessing our pricing and promotional strategy, rebranding our retail pharmacy and ~~EnvisionRxOptions~~pharmacy services business, launching our Store of the Future format and further reducing SG&A and headcount, including integrating certain back office functions in the Pharmacy Services segment both within the segment and across Rite Aid. Other strategic initiatives include the expansion of our digital business, movement to a common client platform at Elixir and investments in talent in sales and underwriting at Elixir.

~~As a result of the restructuring that we announced in March 2019, we achieved annual cost savings of approximately $55.0 million.~~ These ~~savings offset the reduction in TSA fees that we experienced in fiscal 2020. We have implemented further restructuring activities in support of our RxEvolution~~ and other initiatives, which resulted in additional restructuring charges due to further reductions in corporate staffing levels, charges associated with rationalizing SKU’s in our front-end offering and other operational changes. Thesefuture restructuring activities are expected to provide future growth and expense efficiency benefits. ~~We anticipate~~There can be no assurance that our ~~total fiscal 2021 restructuring-related costs to be approximately $60.0 million~~current and ~~expect to realize annualized~~future restructuring charges will achieve the cost savings ~~of approximately $55.0 million over~~and remerchandising benefits in the ~~next two years, although a prolonged impact of COVID-19 could impact the amount and timing of the benefit~~amounts or time anticipated.

3739

Table of Contents

~~recognized. There can be no assurance that we will not incur additional restructuring charges or that we achieve the cost savings in the amounts or time anticipated.~~

Asset Sale to WBA

On September 18, 2017, we entered into the Amended and Restated Asset Purchase Agreement with Walgreens Boots Alliance, Inc. (“WBA”) and Walgreen Co., an Illinois corporation and 100% owned subsidiary of WBA ~~and Buyer,~~(“Buyer”), in which ~~amended and restated in its entirety~~ the ~~previously disclosed Original Asset Purchase Agreement. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement,~~ Buyer purchased from Rite Aid 1,932 ~~Acquired Stores,~~stores, three distribution centers, related inventory and other specified assets and liabilities ~~related thereto~~ for a total purchase price of ~~approximately $4.375 billion,~~$4,375,000, on a cash-free, debt-free basis, in the Sale. We completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA, and received cash proceeds of $4.157 billion.basis.

During fiscal 2019, we completed the sale of one of our distribution centers and related assets to WBA for proceeds of $61.2 million. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $14.2 million, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended March 2, 2019. During fiscal 2020, we completed the sale of the second distribution center and related assets to WBA for proceeds of $62.8 million. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $19.3 million, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended February 29, 2020. During the first quarter of fiscal 2021, we completed the sale of the final distribution center and related assets to WBA for proceeds of ~~$94.3 million.~~$94,289. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of ~~$12.7 million,~~$12,690, which ~~has been~~was included in the results of operations and cash flows of discontinued operations during the thirteen week period ended May 30, 2020. The transfer of the final distribution center and related assets constitutes the final closing under the Amended and Restated Asset Purchase Agreement.

~~We had~~

In connection with the asset sale, we agreed to provide transition services to ~~Buyer for up to three years after the initial closing of the Sale.~~Buyer. Under the terms of the ~~TSA,~~Transition Services Agreement (“TSA”), we provided various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. ~~The term of the TSA had been extended to October 17, 2020, unless earlier terminated.~~ In connection with these services, we purchased the related inventory and incurred cash payments for the selling, general and administrative activities, which, we billed on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen week periods ended May 29, 2021 and May 30, 2020 were $0 and ~~June 1, 2019 were $31.0 million and $1.2 billion,~~$31,005, respectively, of which ~~$4.4 million~~$0 and ~~$224.4 million~~$4,398 is included in Accounts receivable, net. We recorded WBA TSA fees of ~~$1.1 million~~$0 and ~~$14.2 million~~$1,080 during the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively, which are reflected as a reduction to selling, general and administrative expenses. In conjunction with the transfer of the final distribution center during the quarter ended May 30, 2020, we have substantially completed our obligations under the TSA.

Based on its magnitude and because we exited certain markets, the Sale represented a significant strategic shift that ~~has~~had a material effect on our operations and financial results. Accordingly, we have applied discontinued operations treatment for the Sale as required by GAAP.

~~Impact of COVID-19~~

We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and the markets in which we operate, including how it will impact our customers, associates, suppliers, vendors, business partners and supply chain.

~~Rite Aid is on the front lines of providing communities with essential care, services and products and took the following actions during the COVID-19 pandemic to serve its customers and communities:~~

●

~~Worked with the U.S. Department of Health and Human Services to be early adopters of COVID-19 testing, launching 97 sites with the capacity to conduct more than 48,000 tests each week.~~

~~Table of Contents~~

●

Provided additional support specific to associate pay and safety, including our Hero Pay program that ran from March 15 to May 16, 2020, a $1,000 Hero Bonus for retail store management, Pandemic Pay, Administrative Leave, and various in-store safety procedures.

●

~~Through The Rite Aid Foundation, committed $6 million to support healthcare providers and first responders, regional hot spots, community needs and The Rite Aid Foundation Associate Relief Fund.~~

●

~~Hired approximately 6,000 full and part-time associates to support store and distribution center teams.~~

●

~~Instituted “Pandemic Pay” policy that ensures associates are compensated if diagnosed with the virus or quarantined because of exposure.~~

●

Implemented specific internal protocols to keep associates safe and ready to serve customers, including the installation of Plexiglas shields at pharmacy and front-end counters to provide additional protection.

●

~~Ensured contact-less capabilities at our stores for prescription pickup and payment.~~

●

~~Expanded home delivery of front-end items through a new partnership with Instacart.~~

●

~~Launched a new telehealth service Rite Aid Virtual Care to better serve patient needs.~~

●

~~Established social distancing procedures that include marking floor areas in front of the pharmacy and front-end counters with tape to ensure 6-foot separation.~~

●

~~Waived delivery-service fees for eligible prescriptions.~~

●

~~Followed enhanced cleaning and sanitization protocols designed specifically to prevent the spread of a wide spectrum of viruses, including COVID-19 and influenza.~~

The COVID-19 pandemic had a significant impact on our first quarter results. Increased demand for certain front-end products drove a 14.2% increase in front-end comparable store sales. Reduced demand for acute prescriptions due to the doctor’s office closures and the deferral of elective procedures caused a 14.8% reduction in acute prescriptions. Investments in Hero Pay and Hero Bonus programs and additional costs to clean and sanitize stores drove a significant in increase in SG&A expenses. In total, COVID-19 had a net negative impact of $30 million in Adjusted EBITDA in the first quarter.

During the first three weeks of June, we saw continued increases in comparable front-end sales of 7.2% excluding cigarettes and tobacco products over the same prior year period, due to demand for personal care, paper products and OTC medications. We believe our continued strong front-end performance is due to good in-stock positioning through vendor partnerships and store-level execution, success with keeping stores open for longer hours compared to competitors and maintaining a safe and clean store experience for associates and customers. Same store prescription counts during the first three weeks of June increased 80 basis points over the same prior year period due to a lessening impact of acute prescription declines, which decreased by 11.7%.

In addition, we continue to closely manage and reduce costs. We have recently eliminated approximately 250 corporate office positions across both our Retail Pharmacy and Pharmacy Services segments. We have also taken steps to reduce other expenses, such as shrink, advertising, rent, travel and call center expenses. In total, we expect these reductions to result in savings of over $40.0 million in Fiscal 2021 that were not included in our original guidance and over $55.0 million on a run rate basis, although we cannot assure that we will achieve such savings in the amounts or time anticipated. The company expects to incur severance costs of $7.0 million related to the elimination of corporate positions, which will be classified as a restructuring expense.

As of June 25, 2020, we had liquidity of approximately $1.7 billion, which consists of availability to borrow under our secured revolving credit facility of approximately $1.5 billion and cash on hand of approximately $180.0 million.

Overview of Financial Results from Continuing Operations

Our net loss from continuing operations for the thirteen week period ended May ~~30, 2020~~29, 2021 was ~~$72.7~~$13.1 million or ~~$1.36~~$0.24 per basic and diluted share compared to a net loss of ~~$99.3~~$72.7 million or ~~$1.88~~$1.36 per basic and diluted share for the thirteen week period ended ~~June 1, 2019.~~May 30, 2020. The improvement in net loss for the thirteen week period ended May 29, 2021 was due primarily to ~~a LIFO credit~~improved operating results in the ~~current year compared to a LIFO charge~~Retail Pharmacy segment, higher intangible asset impairment charges in the prior year ~~an income tax benefit in the current year compared to income tax expense in the prior year,~~first quarter, and lower restructuring-related costs as a result of last year’s rebranding initiatives. These benefits were partially offset by ~~intangible asset impairment charges relating to~~litigation settlements in the ~~rebranding of the Pharmacy Services Segment to its new brand name, Elixir.~~current quarter, a lower LIFO credit, and an increase in income tax expense.

~~Table of Contents~~

Our Adjusted EBITDA from continuing operations for the thirteen week period ended May ~~30, 2020~~29, 2021 was $138.9 million or 2.3% of revenues, compared to $107.4 million or 1.8% ~~of revenues compared to $110.3 million or 2.1%~~ of revenues, for the thirteen week period ended ~~June 1, 2019.~~May 30, 2020. The ~~decrease~~improvement in Adjusted EBITDA for the thirteen week period ended May ~~30, 2020~~29, 2021 was due to ~~a decrease~~an increase in Adjusted EBITDA in the Retail Pharmacy ~~segment, partially offset by an increase in the Pharmacy Services~~ segment. Adjusted EBITDA ~~decreased $21.0~~increased $31.9 million in the Retail Pharmacy segment due primarily to an increase in gross profit resulting from higher pharmacy same store sales, partially offset by pharmacy reimbursement rate pressures that were not fully offset by generic drug cost reductions and a decline in front end gross profit as we cycled the impact of the prior year’s COVID-19 pandemic in the current year and the benefit from TSA fee income in the prior year. Although our Retail Pharmacy segment benefited from increased front-end sales, the reduction in acute prescription count and incremental expenses for payroll and other operating costs resulted in a combined net negative impact from COVID-19 of approximately $30.0 million in the quarter.buying surge. Adjusted EBITDA ~~increased by $18.1 million~~ in the Pharmacy Services segment ~~due primarily~~was flat to ~~increased revenues and improvements in pharmacy network management.~~the prior year. Please see the sections entitled “Segment Analysis” and “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” below for additional details.

Table of Contents

Consolidated Results of Operations-Continuing Operations

Revenues and Other Operating Data


	Thirteen Week Period Ended						Thirteen Week Period Ended
	May 30,			June 1,			May 29,			May 30,
	2020			2019			2021			2020

	(dollars in thousands except per share amounts)						(dollars in thousands except per share amounts)
Revenues(a)	$	6,027,376		$	5,372,589		$	6,160,985		$	6,027,376
Revenue growth (decline)		12.2	%		(0.3)	%
Revenue growth								2.2	%		12.2	%
Net loss	$	(72,702)		$	(99,339)		$	(13,057)		$	(72,702)
Net loss per diluted share	$	(1.36)		$	(1.88)		$	(0.24)		$	(1.36)
Adjusted EBITDA(b)	$	107,392		$	110,347		$	138,877		$	107,392
Adjusted Net Loss (b)	$	(2,011)		$	(7,519)
Adjusted Net Loss per Diluted Share(b)	$	(0.04)		$	(0.14)
Adjusted Net Income (Loss) (b)							$	20,934		$	(2,011)
Adjusted Net Income (Loss) per Diluted Share(b)							$	0.38		$	(0.04)

(a)	Revenues for the thirteen week periods ended May 29, 2021 and May 30, 2020 exclude $62,979 and ~~June 1, 2019 exclude~~ $73,141, ~~and $58,511,~~ respectively, of inter-segment activity that is eliminated in consolidation.

(b)	See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

Revenues increased 2.2% for the thirteen weeks ended May 29, 2021, compared to an increase of 12.2% for the thirteen weeks ended May 30, ~~2020, compared to a decrease of 0.3% for the thirteen weeks ended June 1, 2019.~~2020. Revenues for the thirteen week period ended May ~~30, 2020~~29, 2021 were positively impacted by a ~~$258.5~~$228.4 million increase in Retail Pharmacy segment revenues, ~~and~~partially offset by a ~~$411.0~~$105.0 million ~~increase~~decrease in Pharmacy Services segment revenues. ~~Same store sales trends for the thirteen week periods ended May 30, 2020 and June 1, 2019 are described in the “Segment Analysis” section below.~~

Please see the section entitled “Segment Analysis” below for additional details regarding revenues.

~~Table of Contents~~

Costs and Expenses


	Thirteen Week Period Ended						Thirteen Week Period Ended
	May 30,			June 1,			May 29,			May 30,
	2020			2019			2021			2020

	(dollars in thousands)						(dollars in thousands)
Cost of revenues(a)	$	4,829,057		$	4,245,866		$	4,876,110		$	4,829,057
Gross profit		1,198,319			1,126,723			1,284,875			1,198,319
Gross margin		19.9	%		21.0	%		20.9	%		19.9	%
Selling, general and administrative expenses	$	1,197,147		$	1,162,652		$	1,245,362		$	1,197,147
Selling, general and administrative expenses as a percentage of revenues		19.9	%		21.6	%		20.2	%		19.9	%
Lease termination and impairment charges		3,753			478
Facility exit and impairment charges								8,831			3,753
Intangible asset impairment charges		29,852			—			—			29,852
Interest expense		50,547			58,270			49,121			50,547
Loss on debt retirements, net								396			—
Gain on sale of assets, net		(2,260)			(2,712)			(6,558)			(2,260)

(a)

Cost of revenues for the thirteen week periods ended May 29, 2021 and May 30, 2020 exclude $62,979 and ~~June 1, 2019 exclude~~ $73,141, ~~and $58,511,~~ respectively, of inter-segment activity that is eliminated in consolidation.

Gross Profit and Cost of Revenues

Gross profit increased by ~~$71.6~~$86.6 million for the thirteen week period ended May ~~30, 2020~~29, 2021 compared to the thirteen week period ended ~~June 1, 2019.~~May 30, 2020. Gross profit for the thirteen week period ended May ~~30, 2020~~29, 2021 includes an

Table of Contents

increase of ~~$51.0~~$88.4 million in our Retail Pharmacy segment, ~~and an increase~~partially offset by a decrease of ~~$20.6~~$1.8 million in our Pharmacy Services segment. Gross margin was 20.9% for the thirteen week period ended May 29, 2021 compared to 19.9% for the thirteen week period ended May 30, ~~2020 compared to 21.0% for the thirteen week period ended June 1, 2019.~~2020. Please see the section entitled “Segment Analysis” for a more detailed description of gross profit and gross margin results by segment.

Selling, General and Administrative Expenses

SG&A increased by ~~$34.5~~$48.2 million for the thirteen week period ended May ~~30, 2020~~29, 2021, compared to the thirteen week period ended ~~June 1, 2019.~~May 30, 2020. The increase in SG&A for the thirteen week period ended May ~~30, 2020~~29, 2021 includes an increase of ~~$37.7~~$47.1 million relating to our Retail Pharmacy segment ~~partially offset by a decrease~~and an increase of ~~$3.2~~$1.2 million relating to our Pharmacy Services segment. Please see the section entitled “Segment Analysis” below for additional details regarding SG&A.

~~Lease Termination~~Facility Exit and Impairment Charges

~~Lease termination~~Facility exit and impairment charges consist of amounts as follows:

Thirteen Week

Period Ended

May 30,

June 1,

2020

2019
Impairment charges

$
2,203

$
123
Lease termination charges

—

—
Facility exit charges

1,550

355

$
3,753

$
478

~~During the thirteen week period ended May 30, 2020, we terminated a software project which resulted in an impairment charge of $1.9 million due to the write-off of the related assets.~~


	Thirteen Week
	Period Ended
	May 29,		May 30,
	2021		2020
Impairment charges	$	4,313	$	2,203
Facility exit charges		4,518		1,550
	$	8,831	$	3,753

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Lease Termination and Impairment Charges” included in our Fiscal ~~2020~~2021 10-K for a detailed description of our impairment and lease termination methodology for fiscal ~~2020.~~2021.

~~Table of Contents~~

Interest Expense

Interest expense was $49.1 million for the thirteen week period ended May 29, 2021, compared to $50.5 million for the thirteen week period ended May 30, ~~2020 compared to $58.3 million for the thirteen week period ended June 1, 2019.~~2020. The weighted average interest rate on our indebtedness for the thirteen week periods ended May 29, 2021 and May 30, 2020 was 5.3% and ~~June 1, 2019 was~~ 4.9% ~~and 5.6%~~, respectively.

Income Taxes

We recorded an income tax expense from continuing operations of $0.8 million and an income tax benefit from continuing operations of $8.0 ~~million and an income tax expense from continuing operations of $7.4~~ million for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. The effective tax rate for the thirteen week periods ended May 29, 2021 and May 30, 2020 was (6.4)% and ~~June 1, 2019 was~~ 9.9% ~~and (8.0)%~~, respectively. The effective tax rate for the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~ was net of an adjustment of ~~(10.6)~~(18.5)% and ~~(34.5)~~(10.6)%, respectively, to adjust the valuation allowance against deferred tax assets.

We recognize tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

We believe that it is reasonably possible that a decrease of up to ~~$13.2~~$11.9 million in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

We regularly evaluate valuation allowances established for deferred tax assets for which future realization is uncertain. We will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. We continue to maintain a valuation allowance against net deferred tax assets of ~~$1,681.4~~$1,660.5 million and ~~$1,673.1~~$1,657.6 million, which relates to federal and

Table of Contents

state deferred tax assets that may not be realized based on our future projections of taxable income at May ~~30, 2020~~29, 2021 and February ~~29, 2020,~~27, 2021, respectively.

Segment Analysis

We evaluate the Retail Pharmacy and Pharmacy Services segments’ performance based on revenue, gross profit, and Adjusted EBITDA. The following is a reconciliation of our segments to the condensed consolidated financial statements:


	Retail		Pharmacy		Intersegment				Retail		Pharmacy		Intersegment
	Pharmacy		Services		Eliminations(1)		Consolidated		Pharmacy		Services		Eliminations(1)		Consolidated
Thirteen Week Period Ended
May 29, 2021:
Revenues									$	4,351,682	$	1,872,282	$	(62,979)	$	6,160,985
Gross Profit										1,169,934		114,941		—		1,284,875
Adjusted EBITDA(*)										94,914		43,963		—		138,877
May 30, 2020:
Revenues	$	4,123,271	$	1,977,246	$	(73,141)	$	6,027,376	$	4,123,271	$	1,977,246	$	(73,141)	$	6,027,376
Gross Profit		1,081,536		116,783		—		1,198,319		1,081,536		116,783		—		1,198,319
Adjusted EBITDA(*)		62,982		44,410		—		107,392		62,982		44,410		—		107,392
June 1, 2019:
Revenues	$	3,864,808	$	1,566,292	$	(58,511)	$	5,372,589
Gross Profit		1,030,495		96,228		—		1,126,723
Adjusted EBITDA(*)		84,008		26,339		—		110,347

(1)

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

4243

Table of Contents

Retail Pharmacy Segment Results of Operations

Revenues and Other Operating Data


	Thirteen Week Period Ended						Thirteen Week Period Ended
	May 30,			June 1,			May 29,			May 30,
	2020			2019			2021			2020

	(dollars in thousands)						(dollars in thousands)
Revenues	$	4,123,271		$	3,864,808		$	4,351,682		$	4,123,271
Revenue growth (decline)		6.7	%		(0.8)	%
Revenue growth								5.5	%		6.7	%
Same store sales growth		6.6	%		1.4	%		1.4	%		6.6	%
Pharmacy sales growth		2.4	%		0.4	%		14.1	%		2.4	%
Same store prescription count growth, adjusted to 30-day equivalents		0.4	%		3.7	%		11.2	%		0.4	%
Same store pharmacy sales growth		2.2	%		2.3	%		8.2	%		2.2	%
Pharmacy sales as a % of total retail sales		64.2	%		67.1	%		68.9	%		64.2	%
Front-end sales growth (decline)		15.8	%		(2.4)	%
Same store front-end sales growth (decline)		14.2	%		(0.3)	%
Front-end sales (decline) growth								(9.8)	%		15.8	%
Same store front-end sales (decline) growth								(12.0)	%		14.2	%
Front-end sales as a % of total retail sales		35.8	%		32.9	%		31.1	%		35.8	%
Adjusted EBITDA(*)	$	62,982		$	84,008		$	94,914		$	62,982
Store data:
Total stores (beginning of period)		2,461			2,469			2,510			2,461
New stores		—			1			1			—
Store acquisitions		—			—			—			—
Closed stores		(4)			(4)			(5)			(4)
Total stores (end of period)		2,457			2,466			2,506			2,457
Relocated stores		—			—			—			—
Remodeled and expanded stores		1			27			6			1

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

Revenues increased 5.5% for the thirteen weeks ended May 29, 2021 compared to an increase of 6.7% for the thirteen weeks ended May 30, ~~2020 compared to a decrease of 0.8% for the thirteen weeks ended June 1, 2019.~~2020. The increase in revenues for the thirteen week period ended May ~~30, 2020~~29, 2021 was primarily a result of an increase in same store ~~sales.~~sales and incremental sales from our recently acquired Bartell stores.

Pharmacy same store sales increased by ~~2.2%~~8.2% for the thirteen week period ended May ~~30, 2020~~29, 2021 compared to an increase of ~~2.3%~~2.2% in the thirteen week period ended ~~June 1, 2019.~~May 30, 2020. The increase in pharmacy same store sales is due to the increase in same store prescription count. Same store prescription count, adjusted to 30-day equivalents, increased ~~0.4%~~11.2% for the thirteen week period ended May ~~30, 2020~~29, 2021 driven primarily by our COVID-19 vaccination program and increases in other acute and maintenance medication fills, supported by personalized Medication Therapy Management interventions and home deliveries, partially offset by a reduction in acute prescriptions of 14.8% resulting from the postponement of outpatient medical visits and elective surgical procedures in connection with the COVID-19 pandemic.prescriptions.

Front-end same store sales ~~increased~~decreased 12.0% during the thirteen week period ended May 29, 2021 compared to an increase of 14.2% during the thirteen week period ended May 30, ~~2020 compared to a decrease of 0.3% during the thirteen week period ended June 1, 2019.~~2020. Front-end same store sales, excluding cigarettes and tobacco products, ~~increased 16.0%~~decreased 11.5%, driven by ~~increases~~decreases in general cleaning products, sanitizers, wipes, paper products, liquor, and over-the-counter products ~~and summer seasonal items, which were~~resulting from the pandemic driven bysurge in the ~~COVID-19 pandemic.~~prior year quarter.

We include in same store sales all stores that have been open at least one year. ~~Relocation~~Relocated and acquired stores are not included in same store sales until one year has lapsed.

4344

Table of Contents

Costs and Expenses


	Thirteen Week Period Ended						Thirteen Week Period Ended
	May 30,			June 1,			May 29,			May 30,
	2020			2019			2021			2020

	(dollars in thousands)						(dollars in thousands)
Cost of revenues	$	3,041,735		$	2,834,313		$	3,181,748		$	3,041,735
Gross profit		1,081,536			1,030,495			1,169,934			1,081,536
Gross margin		26.2	%		26.7	%		26.9	%		26.2	%
FIFO gross profit(*)		1,069,470			1,037,984			1,165,941			1,069,470
FIFO gross margin(*)		25.9	%		26.9	%		26.8	%		25.9	%
Selling, general and administrative expenses	$	1,108,976		$	1,071,325			1,156,039			1,108,976
Selling, general and administrative expenses as a percentage of revenues		26.9	%		27.7	%		26.6	%		26.9	%

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Gross Profit and Cost of Revenues

Gross profit increased ~~$51.0~~$88.4 million for the thirteen week period ended May ~~30, 2020~~29, 2021 compared to the thirteen week period ended ~~June 1, 2019, driven by an~~May 30, 2020. The increase in ~~front-end~~ gross profit ~~resulting from the increase in same store sales, and an increase in pharmacy gross profit~~was driven by higher pharmacy same stores sales ~~volume~~in the current year, incremental gross profit from our recently acquired Bartell stores, and ~~an increase in same store prescription count, partially offset by~~cycling a prior year restructuring charge of $25.8 million related to ~~establish an inventory reserve on~~exiting product lines ~~we are exiting and will no longer carry~~ as part of our rebranding ~~initiative, lower~~initiatives. These increases were partially offset by pharmacy reimbursement ~~rates~~rate pressures that were not fully offset by generic drug cost reductions and ~~lower rebates.~~a decline in front end gross profit as we cycled the impact of the prior year’s COVID-19 buying surge.

Gross margin was 26.9% of sales for the thirteen week period ended May 29, 2021 compared to 26.2% of sales for the thirteen week period ended May 30, ~~2020 compared to 26.7% of sales for the thirteen week period ended June 1, 2019.~~2020. The ~~decline~~improvement in gross margin as a percentage of revenues is due primarily to higher gross margin associated with COVID-19 vaccines and the cycling of the prior year restructuring charge and markdowns related to ~~increased sales volume to our wellness+ members and higher discounts on front-end merchandise provided to our associates in response to~~ the prior year’s COVID-19 ~~pandemic.~~buying surge. These improvements are partially offset by continued pharmacy reimbursement rate pressures that were not fully offset by generic drug cost reductions.

We use the last-in, first-out (“LIFO”) method of inventory valuation, which is estimated on a quarterly basis and is finalized at year end when inflation rates and inventory levels are final. Therefore, LIFO costs for interim period financial statements are estimated. LIFO credits were $4.0 million for the thirteen week period ended May 29, 2021, respectively, compared to LIFO credits of $12.1 million for the thirteen week period ended May 30, ~~2020, compared to LIFO charges of $7.5 million for the thirteen week period ended June 1, 2019.~~2020. The LIFO credit in the thirteen week period ended May ~~30, 2020~~29, 2021 was mostly due to the planned reduction in front-end inventory, ~~resulting from our rebranding initiative.~~partially offset by higher anticipated front-end inflation in fiscal 2022.

Selling, General and Administrative Expenses

SG&A expenses increased ~~$37.7~~$47.1 million for the thirteen week period ended May ~~30, 2020~~29, 2021 due primarily to ~~a reduction in WBA TSA fees~~incremental costs from our recently acquired Bartell stores, costs incurred to support our COVID-19 vaccination program and ~~COVID-19 related expenses, including our~~litigation settlements, partially offset by labor savings due to the cycling of the prior year’s Hero Pay and Hero Bonus programs ~~store cleaning~~ and ~~sanitation and related measures to keep our associates and customers safe.~~the COVID-19 buying surge. SG&A expenses as a percentage of revenues for the thirteen week period ended May ~~30, 2020~~29, 2021 was ~~26.9%~~26.6% compared to ~~27.7%~~26.9% for the thirteen week period ended ~~June 1, 2019.~~May 30, 2020 due primarily to the increase in revenues.

4445

Table of Contents

Pharmacy Services Segment Results of Operations

Revenues and Other Operating Data



	Thirteen Week Period Ended						Thirteen Week Period Ended
	May 30,			June 1,			May 29,			May 30,
	2020			2019			2021			2020

	(dollars in thousands)						(dollars in thousands)
Revenues	$	1,977,246		$	1,566,292		$	1,872,282		$	1,977,246
Revenue growth		26.2	%		1.5	%		(5.3)	%		26.2	%
Adjusted EBITDA(*)	$	44,410		$	26,339		$	43,963		$	44,410

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

~~Pharmacy Services segment revenues~~Revenues decreased $105.0 million for the thirteen week period ended May ~~30, 2020 were $1,977.2 million as~~29, 2021 compared to ~~revenues of $1,566.3 million for~~ the thirteen week period ended ~~June 1, 2019.~~May 30, 2020. The ~~increase~~decrease in revenues ~~for~~was primarily the ~~segment is primarily due to an increase~~result of a decrease in lives stemming from the loss of a large customer account and a decrease in Medicare Part D membership.

Costs and Expenses



	Thirteen Week Period Ended						Thirteen Week Period Ended
	May 30,			June 1,			May 29,			May 30,
	2020			2019			2021			2020

	(dollars in thousands)						(dollars in thousands)
Cost of revenues	$	1,860,463		$	1,470,064		$	1,757,341		$	1,860,463
Gross profit		116,783			96,228			114,941			116,783
Gross margin		5.9	%		6.1	%		6.1	%		5.9	%
Selling, general and administrative expenses	$	88,171		$	91,327			89,323			88,171
Selling, general and administrative expenses as a percentage of revenues		4.5	%		5.8	%		4.8	%		4.5	%

Gross Profit and Cost of Revenues

Gross profit decreased $1.8 million for the thirteen week period ended May ~~30, 2020 was $116.8 million as~~29, 2021 compared to the thirteen week period ended May 30, 2020. The decrease in gross profit is primarily due to the reduction in covered lives in our commercial business and the decrease in our Medicare Part D membership, partially offset by improvements in our discount card business and good network management.

Gross margin was 6.1% of ~~$96.2 million~~sales for the thirteen week period ended ~~June 1, 2019. The increase in the thirteen week period gross profit for the segment is primarily due~~May 29, 2021 compared to ~~increased revenues and improved pharmacy network management.~~

~~Gross margin was~~ 5.9% of sales for the thirteen week period ended May 30, ~~2020 compared to 6.1% of sales for the thirteen week period ended June 1, 2019.~~2020. The ~~decline~~improvement in gross margin is due primarily to improvements in our discount card business and good network management, partially offset by an increase in the medical loss ratio tied to our Medicare Part D ~~membership.~~business.

Selling, General and Administrative Expenses

~~Pharmacy Services segment selling, general~~SG&A expenses increased $1.1 million for the thirteen week period ended May 29, 2021 compared to the thirteen week period ended May 30, 2020 due primarily to increased restructuring charges and higher discount card program costs, partially offset by further consolidation of administrative functions. SG&A expenses as a percentage of revenue was 4.8% for the thirteen week period ended May 29, 2021 compared to 4.5% for the thirteen week period ended May 30, 2020 was $88.2 million as compared to $91.3 million for the thirteen week period ended June 1, 2019. Selling, general and administrative expenses as a percentage of Pharmacy Services segment revenue was 4.5% and 5.8% for the thirteen week periods ended May 30, 2020 and June 1, 2019, respectively.2020. The ~~decrease~~increase in the thirteen week period selling, general and administrative expenses as a percentage of revenues is due primarily to the ~~result~~decrease in revenues relating to the loss of ~~expense control initiatives, partially offset by higher costs associated with supporting~~lives from a large customer account and the ~~increased~~decrease in Medicare Part D membership.

4546

Table of Contents

Liquidity and Capital Resources

General

We have two primary sources of liquidity: (i) cash provided by operating activities and (ii) borrowings under ~~the Existing Facilities.~~our revolving credit facility. Our principal uses of cash are to provide working capital for operations, to service our obligations to pay interest and principal on debt and to fund capital expenditures. Total liquidity as of May ~~30, 2020~~29, 2021 was ~~$1,887.3~~$1,690.2 million, which consisted of revolver borrowing capacity of ~~$1,705.1~~$1,689.0 million and invested cash of ~~$182.2~~$1.2 million.

Credit Facilities

On December 20, 2018, we entered into a senior secured credit agreement (as amended by the First Amendment to Credit Agreement, dated as of January 6, 2020, the “Credit Agreement”), consisting of a $2.7 billion senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a $450.0 million “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan,” and together with the Senior Secured Revolving Credit Facility, collectively, the “Existing Facilities”). We used proceeds from the Existing Facilities to refinance our prior $2.7 billion existing credit agreement (the “Old Facility”). The Existing Facilities extend our debt maturity profile and provide additional liquidity. Borrowings under the Senior Secured Revolving Credit Facility bear interest at a rate per annum between LIBOR plus 1.25% and LIBOR plus 1.75% based upon the Average ABL Availability (as defined in the Credit Agreement). Borrowings under the Senior Secured Term Loan bear interest at a rate per annum of LIBOR plus 3.00%. We are required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Senior Secured Revolving Credit Facility, depending on Average ABL Availability. The Existing Facilities mature on December 20, 2023, subject to an earlier maturity on December 31, 2022 if we have not repaid or refinanced our existing 6.125% Notes prior to such date. We have been engaged in efforts to refinance our existing 6.125% Notes and we intend to repay or refinance any of such outstanding notes prior to the early maturity becoming effective, although we cannot assure you what impact the recent disruption in the financial markets will have on any such efforts.2023.

Our borrowing capacity under the Senior Secured Revolving Credit Facility is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At May ~~30, 2020,~~29, 2021, we had approximately ~~$1,342.0~~$1,339.0 million of borrowings outstanding under the Existing Facilities and had letters of credit outstanding against the Senior Secured Revolving Credit Facility of approximately ~~$102.9~~$122.0 million, which resulted in additional borrowing capacity under the Senior Secured Revolving Credit Facility of ~~$1,705.1~~$1,689.0 million. If at any time the total credit exposure outstanding under the Existing Facilities and the principal amount of our other senior obligations exceed the borrowing base, we will be required to make certain other mandatory prepayments to eliminate such shortfall.

The Credit Agreement restricts us and all of our subsidiaries, including the subsidiaries that guarantee our obligations under the Existing Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the “Subsidiary Guarantors”) from accumulating cash on hand in excess of $200.0 million at any time when revolving loans are outstanding (not including cash located in our store and lockbox deposit accounts and cash necessary to cover our current liabilities). The Credit Agreement also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under the Existing Facilities or (ii) the sum of our borrowing capacity under our Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a “cash sweep period”), the funds in our deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Existing Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of the Existing Facilities.

Our obligations under the Existing Facilities and the Subsidiary Guarantors’ obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of

~~Table of Contents~~

their deposit accounts, collectively, the “ABL priority collateral”) and (ii) a second-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property ~~(following~~

Table of Contents

(following the repayment of the Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations.

The Credit Agreement allows us to have outstanding, at any time, up to an aggregate principal amount of $1.5 billion in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Existing Facilities and other existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date). Subject to the limitations described in the immediately preceding sentence, the Credit Agreement additionally allows us to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Credit Agreement) is not in effect; provided, however, that certain of our other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Credit Agreement also contains certain restrictions on the amount of secured first priority debt we are able to incur. The Credit Agreement also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Existing Facilities are not in default and we maintain availability under our revolver of more than $365.0 million.

The Credit Agreement has a financial covenant that requires us to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Senior Secured Revolving Credit Facility is less than $200.0 million or (ii) on the third consecutive business day on which availability under the Senior Secured Revolving Credit Facility is less than $250.0 million and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250.0 million. As of May ~~30, 2020,~~29, 2021, our fixed charge coverage ratio was greater than 1.00 to 1.00, and we were in compliance with the Credit Agreement’s financial covenant. The Credit Agreement also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.

The Credit Agreement provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if we fail to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment repurchase, redemption or defeasance of such debt.

The indentures that govern our guaranteed unsecured notes and our guaranteed secured notes contain restrictions on the amount of additional secured and unsecured debt that we may incur. As of May ~~30, 2020,~~29, 2021, we had the ability to (i) draw the full amount under our revolving credit facility, or (ii) incur additional secured debt. In addition, we have the ability to enter into certain sale and leaseback transactions. The ability to issue additional unsecured debt under the indenture is generally governed by an interest coverage ratio test. As of May ~~30, 2020,~~29, 2021, we had the ability to issue additional secured and unsecured debt under the indentures governing our unguaranteed unsecured notes.

Guarantor Summarized Financial Information

Certain of our subsidiaries, which are listed on Exhibit 22 to this Quarterly Report on Form 10-Q, have guaranteed our obligations under the 6.125% Notes and the 7.500% Notes (collectively, the "Guaranteed Notes"). As discussed in Note 1112 to the condensed consolidated financial statements, the Guaranteed Notes were issued by us, as the parent company, and are guaranteed by substantially all of the parent company’s consolidated subsidiaries (the “guarantors” or “Subsidiary Guarantors”) except for ~~EIC~~EI (the “non-guarantor”). The parent company and guarantors are referred to as the “obligor group”. The Subsidiary Guarantors fully and unconditionally and jointly and severally guarantee the Guaranteed Notes. The 6.125% Notes and the obligations under the related guarantees are unsecured. The 7.500% Notes and the obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’

~~Table of Contents~~

equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and other collateral to the extent it does not

Table of Contents

constitute ABL priority collateral (as defined below), and (ii) a second-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivables, payment intangibles, inventory, prescription files (including eligible script lists) and, intellectual property (prior to the repayment of the Senior Secured Term Loan) (collectively, the “ABL priority collateral”), which, in each case, also secure the Existing Facilities.

Under certain circumstances, subsidiaries may be released from their guarantees without consent of the note holders. Our subsidiaries conduct substantially all of our operations and have significant liabilities, including trade payables. If the subsidiary guarantees are invalid or unenforceable or are limited by fraudulent conveyance or other laws, the registered debt will be structurally subordinated to the substantial liabilities of our subsidiaries.

Condensed Combined Financial Information

The following tables include summarized financial information of the obligor group. Investments in and the equity in the earnings of ~~EIC,~~EI, which is not a member of the obligor group, have been excluded. The summarized financial information of the obligor group is presented on a combined basis with intercompany balances and transactions between entities in the obligor group eliminated. The obligor group’s amounts due to/from and transactions with ~~EIC~~EI have been presented in separate line items, if material.


	May 30,		February 29,		May 29,		February 27,
In millions	2020		2020		2021		2021
Due from EIC	$	282.6	$	—
Due from EI					$	241.0	$	96.1
Other current assets		3,559.2		3,657.0		3,373.7		3,431.8
Total current assets	$	3,841.8	$	3,657.0	$	3,614.7	$	3,527.9

Operating lease right-of-use assets	$	2,894.3	$	2,903.3	$	3,013.6	$	3,064.1
Goodwill		1,108.1		1,108.1		1,108.1		1,108.1
Other noncurrent assets		1,652.2		1,753.9		1,577.2		1,604.2
Total noncurrent assets	$	5,654.6	$	5,765.3	$	5,698.9	$	5,776.4

Due to EIC	$	—	$	13.3
Due to EI					$	—	$	—
Other current liabilities		2,621.6		2,731.1		2,709.6		2,579.9
Total current liabilities	$	2,621.6	$	2,744.4	$	2,709.6	$	2,579.9

Long-term debt less current maturities	$	3,321.9	$	3,077.3	$	3,014.5	$	3,063.1
Long-term operating lease liabilities		2,694.9		2,710.3		2,771.8		2,829.3
Other noncurrent liabilities		244.2		215.8		213.7		216.9
Total noncurrent liabilities	$	6,261.0	$	6,003.4	$	6,000.0	$	6,109.3

4849

Table of Contents



	Thirteen Week Period Ended		Thirteen Week Period Ended
In millions	May 30, 2020		May 29, 2021
Revenues (a)	$	5,876.3	$	6,019.0
Cost of revenues (b)		4,687.1		4,736.1
Gross profit		1,189.2		1,282.9

Net loss from continuing operations		(71.2)		(8.6)
Net income from discontinued operations		9.2		—
Net loss	$	(62.0)	$	(8.6)

Net loss attributable to Rite Aid	$	(63.5)	$	(13.1)

(a)

Includes ~~$14.2~~$22.2 million of revenues generated from the non-guarantor for the thirteen week period ended May 29, 2021.

(b)

Includes ~~$14.2~~$22.2 million of cost of revenues incurred in transactions with the non-guarantor for the thirteen week period ended May 29, 2021.

Net Cash Provided by/Used in Operating, Investing and Financing Activities

Cash provided by operating activities was $13.9 million compared to cash used in operating activities ~~was~~of $118.3 ~~million and $51.2~~ million for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. Operating cash flow was ~~negatively~~positively impacted by the timing of payments to Elixir’s pharmacy network, a reduction of manufacturer rebates receivables, increases in operating expense accruals and inventory reductions. These are partially offset by growth in our ~~Calendar 2020 Medicare Part D~~CMS receivable ~~timing differences in the receipt of~~and higher receivables from third-party payors mostly due to our monthly capitation payment from CMS, and a temporary build in pharmacy inventory to hedge against any disruptions in the generic supply chain, partially offset by reductions in front-end inventory as we continue to execute on our inventory management initiatives.COVID-19 vaccination program.

Cash used in investing activities was ~~$36.4~~$54.7 million and ~~$48.5~~$36.4 million for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. Cash used for the purchase of property, plant, and equipment was ~~lower~~higher than the prior year due to ~~less~~signage costs associated with our store ~~remodels~~rebranding activities in the current year. During the thirteen week period ended May ~~30, 2020,~~29, 2021, we remodeled ~~1 store and~~six stores, spent ~~$10.7~~$5.4 million on prescription file ~~purchases.~~purchases and received proceeds of $7.5 million from sale-leaseback transactions.

Cash flow used in financing activities was $1.6 million compared to cash provided by financing activities ~~was~~ $212.7 ~~million and $159.2~~ million for the thirteen week periods ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively. Cash ~~provided by~~used in financing activities for the thirteen weeks ended May ~~30, 2020~~29, 2021 reflects the repayment of our 6.125% Notes, partially offset by net revolver borrowings ~~partially offset by~~and the change in ~~outstanding checks.~~our zero balance accounts due to timing of payments.

Capital Expenditures

During the thirteen week periods ended May 29, 2021 and May 30, 2020 ~~and June 1, 2019~~ capital expenditures were as follows:



	Thirteen Week Period Ended				Thirteen Week Period Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020

New store construction, store relocation and store remodel projects	$	6,732	$	20,607	$	33,294	$	6,732
Technology enhancements, improvements to distribution centers and other corporate requirements		21,727		20,374		25,870		21,727
Purchase of prescription files from other retail pharmacies		10,715		8,210		5,436		10,715
Total capital expenditures	$	39,174	$	49,191	$	64,600	$	39,174

Table of Contents

Future Liquidity

We are highly leveraged. Our high level of indebtedness could: (i) limit our ability to obtain additional financing; (ii) limit our flexibility in planning for, or reacting to, changes in our business and the industry; (iii) place us at a competitive disadvantage relative to our competitors with less debt; (iv) render us more vulnerable to general adverse economic and industry conditions, including those resulting from COVID-19; and (v) require us to dedicate a substantial portion of our cash flow to service our debt. Based upon our current levels of operations, we believe that cash flow from operations together with available borrowings under the revolver and other sources of liquidity will be

~~Table of Contents~~

adequate to meet our requirements for working capital, debt service, ~~and~~ capital expenditures and other strategic investments at least for the next twelve months. Based on our liquidity position, which we expect to remain strong, we do not expect to be subject to the minimum fixed charge covenant in the Existing Facilities in the next twelve months. We will continue to assess our liquidity position and potential sources of supplemental liquidity in light of our operating performance, and other relevant circumstances, and we may evaluate alternative sources of liquidity, including further opportunities related to any receivable due to us from CMS, sale and leaseback transactions, and other transactions to optimize our asset base. From time to time, we may seek additional deleveraging or refinancing transactions, including entering into transactions to exchange debt for shares of common stock or other debt securities (including additional secured debt), issuance of equity (including preferred stock and convertible securities), repurchase or redemption of outstanding indebtedness, ~~including our offer to exchange up to $750.0 million aggregate principal amount of the outstanding 6.125% Notes as announced on June 25, 2020,~~ or seek to refinance our outstanding debt (including the Existing Facilities) or may otherwise seek transactions to reduce interest expense and extend debt maturities. We may also look to make additional investments in our business to further our strategic objectives, including targeted acquisitions. Any of these transactions could impact our financial results. ~~We may also use Sale proceeds for one or more of these purposes in accordance with our outstanding agreements.~~

Critical Accounting Policies and Estimates

For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Critical Accounting Policies and Estimates” included in our Fiscal ~~2020~~2021 10-K, which we filed with the SEC on April 27, ~~2020.~~2021.

Factors Affecting Our Future Prospects

For a discussion of risks related to our financial condition, operations and industry, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations” included ~~herein and~~ in our Fiscal ~~2020 10-K, “Part I – Item 1A. Risk Factors” in our Fiscal 2020 10-K and “Part II – Item 1A. Risk Factors” in this Quarterly Report on Form 10-Q.~~2021 10-K.

Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures

In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as “Adjusted EBITDA”, in assessing our operating performance. We believe the non-GAAP measures serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, ~~the WBA merger termination fee,~~ and other items (including stock-based compensation expense, merger and acquisition-related costs, a non-recurring litigation ~~settlement (as further discussed below),~~settlements, severance, restructuring-related costs and costs related to facility closures and gain or loss on sale of assets). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is primarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with comparisons of actual to planned Adjusted EBITDA.

5051

Table of Contents

The following is a reconciliation of our net ~~loss~~income (loss) to Adjusted EBITDA for the thirteen week periods ended May 29, 2021 and May 30, ~~2020 and June 1, 2019:~~2020:


	Thirteen Week Period Ended				Thirteen Week Period Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020

	(dollars in thousands)				(dollars in thousands)
Net loss from continuing operations	$	(72,702)	$	(99,339)	$	(13,057)	$	(72,702)
Interest expense		50,547		58,270		49,121		50,547
Income tax (benefit) expense		(8,018)		7,374
Income tax expense (benefit)						780		(8,018)
Depreciation and amortization		79,103		83,926		75,859		79,103
LIFO (credit) charge		(12,066)		7,489
Lease termination and impairment charges		3,753		478
LIFO credit						(3,993)		(12,066)
Facility exit and impairment charges						8,831		3,753
Intangible asset impairment charges		29,852		—		—		29,852
Loss on debt retirements, net						396		—
Merger and Acquisition‑related costs		—		3,085		3,886		—
Stock-based compensation expense		1,874		5,380		2,811		1,874
Restructuring-related costs		35,735		43,350		5,932		35,735
Inventory write-downs related to store closings		834		841		472		834
Litigation settlements						14,000		—
Gain on sale of assets, net		(2,260)		(2,712)		(6,558)		(2,260)
Other		740		2,205		397		740
Adjusted EBITDA from continuing operations	$	107,392	$	110,347	$	138,877	$	107,392

The following is a reconciliation of our net income (loss) from continuing operations to Adjusted Net Income (Loss) ~~Income~~ and Adjusted Net Income (Loss) ~~Income~~ per Diluted Share for the thirteen week periods ended May 29, 2021 and May 30, ~~2020 and June 1, 2019.~~2020. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization expense, merger and acquisition-related costs, a non-recurring litigation ~~settlement (as further discussed below),~~settlements, gains or losses on debt modifications and retirements, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), goodwill and intangible asset impairment charges, and restructuring-related ~~costs and the WBA merger termination fee.~~costs. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share are useful indicators of our operating performance over multiple periods. ~~Adjusted Net Income (Loss) per Diluted Share is calculated using our above-referenced definition of Adjusted Net Income (Loss):~~


	Thirteen Week Period Ended				Thirteen Week Period Ended
	May 30,		June 1,		May 29,		May 30,
	2020		2019		2021		2020

	(dollars in thousands)				(dollars in thousands)
Net loss	$	(72,702)	$	(99,339)	$	(13,057)	$	(72,702)
Add back - Income tax (benefit) expense		(8,018)		7,374
Add back - Income tax expense (benefit)						780		(8,018)
Loss before income taxes		(80,720)		(91,965)		(12,277)		(80,720)
Adjustments:
Amortization expense		24,420		27,660		20,460		24,420
LIFO (credit) charge		(12,066)		7,489
LIFO credit						(3,993)		(12,066)
Intangible asset impairment charges		29,852		—		—		29,852
Loss on debt retirements, net						396		—
Merger and Acquisition‑related costs		—		3,085		3,886		—
Restructuring-related costs		35,735		43,350		5,932		35,735
Adjusted loss before income taxes		(2,779)		(10,381)
Adjusted income tax benefit (a)		(768)		(2,862)
Adjusted net loss		(2,011)	$	(7,519)
Litigation settlements						14,000		—
Adjusted income (loss) before income taxes						28,404		(2,779)
Adjusted income tax expense (benefit) (a)						7,470		(768)
Adjusted net income (loss)					$	20,934	$	(2,011)
Net loss per diluted share	$	(1.36)	$	(1.88)	$	(0.24)	$	(1.36)
Adjusted net loss per diluted share	$	(0.04)	$	(0.14)
Adjusted net income (loss) per diluted share					$	0.38	$	(0.04)

Table of Contents

(a)

The fiscal year ~~2021~~2022 and ~~2020~~2021 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL’s, state credits and valuation allowance, was used for the thirteen weeks ended May 29, 2021 and May 30, 2020, ~~and June 1, 2019,~~ respectively.

~~Table of Contents~~

In addition to Adjusted EBITDA, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of our business and how we utilize them to describe our results. These measures include but are not limited to Adjusted EBITDA Gross Margin and Gross Profit (gross margin/gross profit excluding non-Adjusted EBITDA items), Adjusted EBITDA SG&A (SG&A expenses excluding non-Adjusted EBITDA items), FIFO Gross Margin and FIFO Gross Profit (gross margin/gross profit before LIFO charges), and Free Cash Flow (Adjusted EBITDA less cash paid for interest, rent on closed stores, capital expenditures, ~~acquisition~~restructuring-related costs and the change in working capital).

We include these non-GAAP financial measures in our earnings announcements in order to provide transparency to our investors and enable investors to better compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share or other non-GAAP measures should not be considered in isolation from, and are not intended to represent an alternative measure of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. Our definition of these non-GAAP measures may not be comparable to similarly titled measurements reported by other companies.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Our future earnings, cash flow and fair values relevant to financial instruments are dependent upon prevalent market rates. Market risk is the risk of loss from adverse changes in market prices and interest rates. Our major market risk exposure is changing interest rates. Increases in interest rates would increase our interest expense. We enter into debt obligations to support capital expenditures, acquisitions, working capital needs and general corporate purposes. Our policy is to manage interest rates through the use of a combination of variable-rate credit facilities, fixed-rate long-term obligations and derivative transactions.

The table below provides information about our financial instruments that are sensitive to changes in interest rates. The table presents principal payments and the related weighted average interest rates by expected maturity dates as of May ~~30, 2020 and assumes that we have repaid or refinanced our existing 6.125% Notes prior to December 31, 2022.~~29, 2021.


																						Fair Value at																							Fair Value at
	2021			2022			2023			2024			2025			Thereafter			Total			May 30, 2020		2022			2023			2024			2025			2026			Thereafter			Total			May 29, 2021

	(Dollars in thousands)																							(Dollars in thousands)
Long-term debt, including current portion, excluding financing lease obligations
Fixed Rate	$	—		$	—		$	—		$	1,153,490		$	—		$	866,387		$	2,019,877		$	1,864,395	$	—		$	—		$	—		$	—		$	600,000		$	1,116,305		$	1,716,305		$	1,761,602
Average Interest Rate		0.00	%		0.00	%		0.00	%		6.13	%		0.00	%		7.53	%		6.73	%				0.00	%		0.00	%		0.00	%		0.00	%		7.50	%		7.91	%		7.76	%
Variable Rate	$	—		$	—		$	—		$	1,342,000		$	—		$	—		$	1,342,000		$	1,342,000	$	—		$	—		$	1,339,000		$	—		$	—		$	—		$	1,339,000		$	1,339,000
Average Interest Rate		0.00	%		0.00	%		0.00	%		2.60	%		0.00	%		0.00	%		2.60	%				0.00	%		0.00	%		2.17	%		0.00	%		0.00	%		0.00	%		2.17	%

Our ability to satisfy interest payment obligations on our outstanding debt will depend largely on our future performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. If we do not have sufficient cash flow to service our interest payment obligations on our outstanding indebtedness and if we cannot borrow or obtain equity financing to satisfy those obligations, our business and results of operations could be materially adversely affected. We cannot be assured that any replacement borrowing or equity financing could be successfully completed.

The interest rate on our variable rate borrowings, which include our revolving credit facility and our term loan facility, are based on LIBOR. If the market rates of interest for LIBOR changed by 100 basis points as of May ~~30, 2020,~~29, 2021, our annual interest expense would change by approximately $13.4 million.

Table of Contents

A change in interest rates does not have an impact upon our future earnings and cash flow for fixed-rate debt instruments. As fixed-rate debt matures, however, and if additional debt is acquired to fund the debt repayment, future earnings and cash flow may be affected by changes in interest rates. This effect would be realized in the periods subsequent to the periods when the debt matures. Increases in interest rates would also impact our ability to refinance existing maturities on favorable terms.

~~Table of Contents~~

ITEM 4. Controls and Procedures

(a) Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.

(b) Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

5354

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings

The information in response to this item is incorporated herein by reference to Note ~~15,~~16, Commitments, Contingencies and Guarantees, of the Consolidated Condensed Financial Statements of this Quarterly Report.

ITEM 1A. Risk Factors

~~The following risk factor~~In addition to the information set forth in this Quarterly Report, you should ~~be read in conjunction with our risk~~carefully consider the factors discussed in “Part I — Item 1A. Risk Factors” in our Fiscal ~~2020~~2021 10-K, which could materially affect our business, financial condition or future results. ~~Except as set forth below, the risk factors described in our Fiscal 2020 10-K have not materially changed.~~

~~Widespread health developments, including the global COVID-19 pandemic, could materially and adversely affect our business, financial condition and results of operations.~~

We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and the markets in which we have stores or otherwise operate. This pandemic, as well as the reality or fear of any other adverse public health developments, has impacted and could further adversely and materially affect, among other things, our workforce, operations, stores, and supply chain, and the operations of our customers, suppliers and business partners. The pandemic has also impacted purchasing decisions of our customers. Separately, a limited number of stores have been damaged or have been required to close as a result of recent civil unrest. The local, national and international response to the virus is quickly developing, fluid and uncertain. Responses have included voluntary, and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social, medical and other activities, and declarations of emergencies. Such measures have contributed to the sudden increase in the unemployment rate and changes in customer spending. Any such negative impact could result in a material adverse effect on our business, financial conditions and results of operations.

In response to the spread of COVID-19, we have modified certain of our business practices (including store hours and access, employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our associates, customers, suppliers and business partners. There is no certainty that such measures will be sufficient to mitigate the risks posed by the virus, and our ability to perform critical functions could be negatively impacted. Further, the initiatives we have implemented to slow and/or reduce the impact of COVID-19 and the related support programs we have put in place for our associates and customers have in some instances, increased our operating expenses and reduced the efficiency of our operations. There can be no assurance that a continued effect of COVID-19 will not impact the measures we have taken to reduce costs.

We have incurred additional costs to ensure we meet the safety and needs of our associates and customers, including the installation of Plexiglas shields at pharmacy and front-end counters to provide additional protection, providing additional cleaning materials for our stores and other facilities, and focusing on home delivery and digital services. In addition, we temporarily enhanced certain employee benefits and compensation for those on the front-line. We expect to continue to incur additional costs, which may be significant, as we continue to implement operational changes in response to this pandemic.

COVID-19 may also cause supply chain disruption which could result in higher supply chain costs to replenish inventory in our stores and distribution centers. In addition, we may experience shortages in our generic drug supplies due to replenishment delays resulting from COVID-19, which could result in the substitution of generic drugs with brand drugs, which generally have a lower profit margin. Furthermore, we have experienced and may continue to experience restricted stock availability in a number of categories, which may cause us to change our purchasing decisions across many categories, and we cannot assure you whether these delays or difficulty sourcing certain products will continue, which could negatively impact us.

~~Table of Contents~~

COVID-19 has also significantly impacted some of our counterparties and may continue to do so in the future. For example, GNC, with whom we have a strategic alliance under which we have opened over 1,623 GNC stores within Rite Aid stores as of February 29, 2020 and have a contractual commitment to open at least 99 additional GNC stores within Rite Aid stores by December 2021, recently filed for bankruptcy. There can be no assurance as to what the impact of GNC’s bankruptcy will be on our relationship with GNC.

Further, our management is focused on mitigating COVID-19, which has required and will continue to require, a large investment of time and resources across the company and may delay other value added services. COVID-19 or any other adverse public health developments could inhibit or delay our ability to execute our strategic initiatives, including, without limitation, (i) improving our pharmacy benefit management business, (ii) redefining the role of our pharmacists, including bringing pharmacists front and center and out from behind the counter, (iii) updating our retail and digital experience; (iv) the roll-out of our future store concept, merchandising changes and rebranding efforts; and (v) our plan to increase the sales volume and profitability of our existing brands. Additionally, the impact of COVID-19 on our business may be impacted by the costs of treatment of COVID-19, unemployment, and the related effects on customer insurance coverage caused by governmental actions to mitigate the impact of COVID-19 or other adverse public health developments, including reduced demand for acute medication. In response to COVID-19, we have announced the deferral of our planned capital expenditures.

The extent to which COVID-19 may impact our business depends on numerous evolving factors, which are highly uncertain and cannot be predicted and are outside of our control, including new information which may quickly emerge concerning the severity of the virus, the scope of the outbreak and the actions to contain the virus or treat its impact and the disruption, volatility in the global capital markets, which may increase the cost of capital and adversely impact our access to capital and to what extent normal economic and operating conditions can resume, among others. As a result, the impact on our financial and operating results cannot be reasonably estimated at this time, but the impact could be material. The continued impact of COVID-19 resulted in us withdrawing our previously issued outlook for fiscal 2021 when we released earnings on June 25, 2020.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Repurchases of Equity Securities. The table below is a listing of repurchases of common stock during the first quarter of fiscal ~~2021.~~2022.


	Total			Total Number of Shares	Maximum Number of	Total			Total Number of Shares	Maximum Number of
	Number of	Average		Purchased as Part of	Shares that may yet be	Number of	Average		Purchased as Part of	Shares that may yet be
	Shares	Price Paid		Publicly Announced	Purchased under the	Shares	Price Paid		Publicly Announced	Purchased under the
Fiscal period:	Repurchased	Per Share		Plans or Programs	Plans or Programs	Repurchased	Per Share		Plans or Programs	Plans or Programs
March 1 to March 28, 2020	7	$	14.03	—	—
March 29 to April 25, 2020	—	$	—	—	—
April 26 to May 30, 2020	—	$	—	—	—
February 28, 2021 to March 27, 2021						—	$	—	—	—
March 28 to April 24, 2021						1	$	21.36	—	—
April 25 to May 29, 2021						1	$	19.09	—	—

ITEM 3. Defaults Upon Senior Securities

Not applicable.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information

Not applicable.

~~Table of Contents~~

ITEM 6. Exhibits

(a)

The following exhibits are filed as part of this report.


Exhibit Numbers	Description	Incorporation By Reference To
2.1	Amended and Restated Asset Purchase Agreement, dated September 18, 2017, among Rite Aid Corporation, Walgreens Boots Alliance, Inc. and Walgreen Co.**	Exhibit 2.1 to Form 8-K, filed on September 19, 2017
2.2	~~Termination Agreement, dated as of August 8, 2018, among Rite Aid Corporation, Albertsons Companies, Inc., Ranch Acquisition II LLC and Ranch Acquisition Corp.~~	~~Exhibit 2.1 to Form 8-K, filed on August 8, 2018~~
~~2.3~~	Receivable Purchase Agreement, dated as of February 19, 2020, by and between Envision Insurance Company and Part D Receivable Trust 2020-1 (Series A)	Exhibit 2.1 to Form 8-K, filed on February 21, 2020
~~2.4~~2.3	Indemnity Agreement, dated as of February 19, 2020 by and between Rite Aid Corporation and Part D Receivable Trust 2020-1 (Series A)	Exhibit 2.2 to Form 8-K, filed on February 21, 2020
3.1	Amended and Restated Certificate of Incorporation	Exhibit 3.1 to Form 8-K, filed on April 18, 2019

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
3.2	Amended and Restated By-Laws	Exhibit 3.1 to Form 8-K, filed on April 17, 2020
4.1	Indenture, dated as of August 1, 1993, between Rite Aid Corporation, as issuer, and Morgan Guaranty Trust Company of New York, as trustee, related to the Company’s 7.70% Notes due 2027	Exhibit 4A to Registration Statement on Form S-3, File No. 033-63794, filed on June 3, 1993
4.2	Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and U.S. Bank Trust National Association (as successor trustee to Morgan Guaranty Trust Company of New York) to the Indenture dated as of August 1, 1993, between Rite Aid Corporation and Morgan Guaranty Trust Company of New York, relating to the Company’s 7.70% Notes due 2027	Exhibit 4.1 to Form 8-K filed on February 7, 2000
4.3	Indenture, dated as of December 21, 1998, between Rite Aid Corporation, as issuer, and Harris Trust and Savings Bank, as trustee, related to the Company’s 6.875% Notes due 2028	Exhibit 4.1 to Registration Statement on Form S-4, File No. 333-74751, filed on March 19, 1999
4.4	Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and Harris Trust and Savings Bank to the Indenture, dated December 21, 1998, between Rite Aid Corporation and Harris Trust and Savings Bank, related to the Company’s 6.875% Notes due 2028	Exhibit 4.4 to Form 8-K, filed on February 7, 2000
4.5	Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.1 to Form 8-K, filed on April 2, 2015
4.6	Supplemental Indenture, dated as of August 23, 2018, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.1 to Form 8-K filed on August 23, 2018

~~Table of Contents~~


~~Exhibit~~ ~~Numbers~~	~~Description~~	~~Incorporation By Reference To~~
4.7	Supplemental Indenture, dated as of February 8, 2019, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.9 to Form 10-K filed on April 25, 2019
4.8	Indenture, dated as of February 5, 2020, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 7.500% Senior Secured Notes due 2025	Exhibit 4.1 to Form 8-K filed on February 5, 2020
4.9	Description of the Company’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934	Exhibit 4.9 to Form 10-K filed on April 27, 2020
4.10	Indenture, dated as of July 27, 2020, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 8.000% Senior Secured Notes due 2026	Exhibit 4.1 to Form 8-K filed on July 27, 2020

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
4.11	Supplemental Indenture, dated as of July 9, 2020, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.3 to Form 8-K filed on July 27, 2020
10.1	2010 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 25, 2010
10.2	Amendment No. 1, dated September 21, 2010, to the 2010 Omnibus Equity Plan	Exhibit 10.7 to Form 10-Q, filed on October 7, 2010
10.3	Amendment No. 2, dated January 16, 2013, to the 2010 Omnibus Equity Plan	Exhibit 10.8 to Form 10-K, filed on April 23, 2013
10.4	2012 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 25, 2012
10.5	Amendment No. 1, dated January 16, 2013, to the 2012 Omnibus Equity Plan	Exhibit 10.10 to Form 10-K, filed on April 23, 2013
10.6	2014 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 23, 2014
10.7	Form of Award Agreement	Exhibit 10.2 to Form 8-K, filed on May 15, 2012
10.8	~~Supplemental Executive Retirement Plan~~	~~Exhibit 10.6 to Form 10-K, filed on April 28, 2010~~
~~10.9~~	Executive Incentive Plan for Officers of Rite Aid Corporation	Exhibit 10.1 to Form 8-K, filed on February 24, 2012
~~10.10~~	~~Amended and Restated Employment Agreement by and between Rite Aid Corporation and John T. Standley, dated as of January 21, 2010~~	~~Exhibit 10.7 to Form 10-K, filed on April 28, 2010~~
~~10.11~~	~~Employment Agreement, dated as of July 24, 2014, by and between Rite Aid Corporation and Darren W. Karst~~	~~Exhibit 10.2 to Form 10-Q, filed on October 2, 2014~~
~~10.12~~	~~Letter Agreement, dated October 26, 2015, to the Employment Agreement by and between Rite Aid Corporation and Darren W. Karst, dated as of July 24, 2014~~	~~Exhibit 10.1 to Form 8-K, filed on October 28, 2015~~
~~10.13~~10.9	Employment Agreement by and between Rite Aid Corporation and Jocelyn Konrad dated as of August 18, 2015	Exhibit 10.1 to Form 10-Q, filed on January 6, 2016
~~10.14~~	~~Employment Agreement by and between Rite Aid Corporation and Bryan Everett dated as of June 22, 2015~~	~~Exhibit 10.2 to Form 10-Q, filed on January 6, 2016~~
~~10.15~~	~~Form of Retention Award Agreement~~	~~Exhibit 10.1 to Form 8-K, filed on January 7, 2016~~
~~10.16~~	~~Form of December 31, 2015 Retention Award Agreement~~	~~Exhibit 10.2 to Form 8-K, filed on January 7, 2016~~
~~10.17~~10.10	Credit Agreement, dated as of December 20, 2018, among Rite Aid Corporation, the lenders from time to time party thereto and Bank of America, N.A., as administrative agent and collateral agent.	Exhibit 10.1 to Form 8-K, filed on December 20, 2018

~~Table of Contents~~


~~Exhibit~~ ~~Numbers~~	~~Description~~	~~Incorporation By Reference To~~
~~10.18~~10.11	Amended and Restated Collateral Trust and Intercreditor Agreement, including the related definitions annex, dated as of June 5, 2009, among Rite Aid Corporation, each subsidiary named therein or which becomes a party thereto, Wilmington Trust Company, as collateral trustee, Citicorp North America, Inc., as senior collateral processing agent, The Bank of New York Trust Company, N.A., as trustee under the 2017 7.5% Note Indenture (as defined therein) and The Bank of New York Mellon Trust Company, N.A., as trustee under the 2016 10.375% Note Indenture (as defined therein), and each other Second Priority Representative and Senior Representative which becomes a party thereto	Exhibit 10.3 to Form 8-K, filed on June 11, 2009

~~10.19~~	~~Employment Agreement by and between RxOptions, LLC and its affiliates operating the EnvisionRXOptions business and Ben Bulkley dated February 15, 2019~~	~~Exhibit 10.27 to Form 10-K, filed on April 25, 2019~~
~~10.20~~	~~Separation Agreement by and between Rite Aid Corporation and John T. Standley, dated as of March 12, 2019~~	~~Exhibit 10.28 to Form 10-Q, filed on July 11, 2019~~
~~10.21~~	~~Separation Agreement by and between Rite Aid Corporation and Darren Karst, dated as of March 12, 2019~~	~~Exhibit 10.29 to Form 10-Q, filed on July 11, 2019~~
~~10.22~~	~~Separation Agreement by and between Rite Aid Corporation and Kermit Crawford, dated as of March 12, 2019~~	~~Exhibit 10.30 to Form 10-Q, filed on July 11, 2019~~
~~10.23~~	~~Amendment to Employment Agreement by and between Rite Aid Corporation and Bryan Everett, dated as of March 12, 2019~~	~~Exhibit 10.31 to Form 10-Q, filed on July 11, 2019~~
~~10.24~~10.12	Amendment to Employment Agreement by and between Rite Aid Corporation and Jocelyn Z. Konrad, dated as of March 12, 2019	Exhibit 10.32 to Form 10-Q, filed on July 11, 2019
~~10.25~~10.13	Amendment to Employment Agreement by and between Rite Aid Corporation and Matthew C. Schroeder, dated as of March 12, 2019	Exhibit 10.33 to Form 10-Q, filed on July 11, 2019
~~10.26~~10.14	Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of March 12, 2019	Exhibit 10.34 to Form 10-Q, filed on July 11, 2019
~~10.27~~10.15	Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of December 5, 2017	Exhibit 10.35 to Form 10-Q, filed on July 11, 2019
~~10.28~~	~~Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of August 10, 2016~~	~~Exhibit 10.36 to Form 10-Q, filed on July 11, 2019~~
~~10.29~~	~~Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of January 1, 2001~~	~~Exhibit 10.37 to Form 10-Q, filed on July 11, 2019~~
~~10.30~~	Eleventh Amendment to Supply Agreement by and between Rite Aid Corporation and McKesson Corporation, dated as of February 28, 2019*	~~Exhibit 10.38 to Form 10-Q, filed on July 11, 2019~~
~~10.31~~	Employment Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 8, 2019**	~~Exhibit 10.1 to Form 8-K, filed on August 12, 2019~~
~~10.32~~	~~Employment Inducement Award Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 12, 2019~~	~~Exhibit 10.2 to Form 8-K, filed on August 12, 2019~~

5857

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
~~10.33~~10.16	~~Consulting~~Amendment to Employment Agreement by and between Rite Aid Corporation and ~~Avalon Retail Consulting, Inc., through its president, John T. Standley,~~Brian Hoover, dated as of August 10, 2016	Exhibit 10.36 to Form 10-Q, filed on July 11, 2019
10.17	Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of January 1, 2001	Exhibit 10.37 to Form 10-Q, filed on July 11, 2019
10.18	Eleventh Amendment to Supply Agreement by and between Rite Aid Corporation and McKesson Corporation, dated as of February 28, 2019*	Exhibit 10.38 to Form 10-Q, filed on July 11, 2019
10.19	Employment Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August ~~14, 2019~~8, 2019**	Exhibit 10.1 to Form 8-K, filed on August ~~16,~~12, 2019
~~10.34~~10.20	Employment Inducement Award Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 12, 2019	Exhibit 10.2 to Form 8-K, filed on August 12, 2019
10.21	Employment Agreement dated October 2, 2019 by and between Rite Aid Corporation and James Peters	Exhibit 10.1 to Form 8-K, filed on October 2, 2019
~~10.35~~	~~Separation Agreement dated October 2, 2019 by and between Rite Aid Corporation and Bryan Everett~~	~~Exhibit 10.2 to Form 8-K, filed on October 2, 2019~~
~~10.36~~	~~Consulting Agreement dated October 2, 2019 by and between Rite Aid Corporation and Bryan Everett~~	~~Exhibit 10.3 to Form 8-K, filed on October 2, 2019~~
~~10.37~~10.22	Employment Agreement by and between Rite Aid Corporation and James J. Comitale, dated as of October 26, 2015	Exhibit 10.41 to Form 10-K filed on April 27, 2020
~~10.38~~10.23	Amendment to Employment Agreement by and between James J. Comitale, dated November 6, 2019	Exhibit 10.42 to Form 10-K filed on April 27, 2020
~~10.39~~10.24	Employment Agreement by and between Rite Aid Corporation and Jessica Kazmaier, dated as of March 12, 2019	Exhibit 10.43 to Form 10-K filed on April 27, 2020
~~10.40~~10.25	Amendment to Employment Agreement by and between Jessica Kazmaier, dated November 6, 2019	Exhibit 10.44 to Form 10-K filed on April 27, 2020
~~10.41~~10.26	Employment Agreement by and between Justin Mennen, dated as of December 7, 2018	Exhibit 10.45 to Form 10-K filed on April 27, 2020
~~10.42~~10.27	Amendment to Employment Agreement by and between Justin Mennen, dated November 6, 2019	Exhibit 10.46 to Form 10-K filed on April 27, 2020
~~10.43~~10.28	Employment Agreement by and between Rite Aid Corporation and Andre Persaud, dated as of January 28, 2020	Exhibit 10.47 to Form 10-K filed on April 27, 2020
~~10.44~~10.29	Employment Agreement by and between RxOptions, LLC and Dan Robson, dated as of December 12, 2019	Exhibit 10.48 to Form 10-K filed on April 27, 2020
~~10.45~~10.30	Separation Agreement by and between Rite Aid Corporation and James C. Comitale, as of May 21, 2020	~~Filed herewith~~Exhibit 10.45 to Form 10-Q filed on July 2, 2020
10.31	Employment Agreement by and between Rite Aid Corporation and Paul D. Gilbert, as of July 29, 2020	Exhibit 10.46 to Form 10-Q filed on October 6, 2020
10.32	Separation Agreement by and between Rite Aid Corporation and Dan Robson, as of January 27, 2021*	Exhibit 10.32 to Form 10-K filed on April 27, 2021
10.33	Rite Aid Corporation 2020 Omnibus Equity Plan	Appendix B to Schedule 14A (Definitive Proxy Statement) filed on May 26, 2020
10.34	Form Award Agreement (Executive) under the Rite Aid Corporation 2020 Omnibus Equity Plan	Exhibit 10.2 to Form 8-K filed on July 8, 2020
10.35	Form Award Agreement (Non-employee Director) under the Rite Aid Corporation 2020 Omnibus Equity Plan	Exhibit 10.3 to Form 8-K filed on July 8, 2020
22	List of Subsidiary Guarantors	Filed herewith
31.1	Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
31.2	Certification of CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
32	Certification of CEO and CFO pursuant to 18 United States Code, Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.	Filed herewith
101.SCH	XBRL Taxonomy Extension Schema Document.	Filed herewith
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.	Filed herewith
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.	Filed herewith
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.	Filed herewith
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.	Filed herewith
104	Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.	Filed herewith

* Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

~~Table of Contents~~

** Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

6059

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: July ~~2, 2020~~6, 2021	RITE AID CORPORATION

	By:	/s/ MATTHEW C. SCHROEDER
		Matthew C. Schroeder
		Executive Vice President and Chief Financial Officer

Date: July ~~2, 2020~~6, 2021	By:	/s/ BRIAN T. HOOVER
		Brian T. Hoover
		Senior Vice President and Chief Accounting Officer

6160